<SEC-DOCUMENT>0001096906-22-002547.txt : 20221025
<SEC-HEADER>0001096906-22-002547.hdr.sgml : 20221025
<ACCEPTANCE-DATETIME>20221025144837
ACCESSION NUMBER:		0001096906-22-002547
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20221025
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20221025
DATE AS OF CHANGE:		20221025

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			UTAH MEDICAL PRODUCTS INC
		CENTRAL INDEX KEY:			0000706698
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				870342734
		STATE OF INCORPORATION:			UT
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12575
		FILM NUMBER:		221329030

	BUSINESS ADDRESS:	
		STREET 1:		7043 S 300 WEST
		CITY:			MIDVALE
		STATE:			UT
		ZIP:			84047
		BUSINESS PHONE:		8015661200
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>utmd-20221025.htm
<DESCRIPTION>UTAH MEDICAL PRODUCTS, INC. - FORM 8-K SEC FILING
<TEXT>
<XBRL>
<?xml version='1.0' encoding='us-ascii' standalone='no'?>
<html xmlns='http://www.w3.org/1999/xhtml' xmlns:xbrli='http://www.xbrl.org/2003/instance' xmlns:dei='http://xbrl.sec.gov/dei/2021q4' xmlns:i='http://www.xbrl.org/2003/instance' xmlns:xbrldi='http://xbrl.org/2006/xbrldi' xmlns:iso4217='http://www.xbrl.org/2003/iso4217' xmlns:ix='http://www.xbrl.org/2013/inlineXBRL' xmlns:ixt='http://www.xbrl.org/inlineXBRL/transformation/2015-02-26' xmlns:ixt-sec='http://www.sec.gov/inlineXBRL/transformation/2015-08-31' xmlns:utr='http://www.xbrl.org/2009/utr' xmlns:link='http://www.xbrl.org/2003/linkbase' xmlns:xlink='http://www.w3.org/1999/xlink' xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance'>
<head>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2022 [PPXK5GW761L0VGS139PY]. www.edgarsuite.com -->
<title>UTAH MEDICAL PRODUCTS, INC. - Form 8-K SEC filing</title>
<meta content='text/html; charset=UTF-8' http-equiv='Content-Type' />
</head>
<body>
<div style='display:none'>
<ix:header>
<ix:hidden>
<ix:nonNumeric name='dei:EntityCentralIndexKey' contextRef='D221025' id='fact1'>0000706698</ix:nonNumeric>
<ix:nonNumeric name='dei:AmendmentFlag' contextRef='D221025' id='fact2'>false</ix:nonNumeric>
</ix:hidden>
<ix:references>
<link:schemaRef xlink:arcrole='http://www.xbrl.org/2003/linkbase' xlink:href='utmd-20221025.xsd' xlink:type='simple'/>
</ix:references>
<ix:resources>
<i:context id='D221025'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
</i:entity>
<i:period>
<i:startDate>2022-10-25</i:startDate>
<i:endDate>2022-10-25</i:endDate>
</i:period>
</i:context>
</ix:resources>
</ix:header>
</div>
<div style='margin-left:72pt;width:468pt'><hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:14pt Times New Roman;margin:0;text-align:center'><b>SECURITIES AND EXCHANGE COMMISSION</b></p>
<p style='font:15pt Times New Roman;margin:0;text-align:center'><b>Washington, D.C. &#160;20549</b></p>
<p style='font:15pt Times New Roman;margin:0;text-align:center'>&#160;</p>
<p style='font:14pt Times New Roman;margin:0;text-align:center'><b>FORM <ix:nonNumeric name='dei:DocumentType' contextRef='D221025' escape='true'>8-K</ix:nonNumeric></b></p>
<p style='font:14pt Times New Roman;margin:0;text-align:center'>&#160;</p>
<p style='font:14pt Times New Roman;margin:0;text-align:center'><b>CURRENT REPORT</b></p>
<p style='font:14pt Times New Roman;margin:0;text-align:center'>&#160;</p>
<p style='font:12pt Times New Roman;margin:0;text-align:center'><b>Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</b></p>
<p style='font:11pt Times New Roman;margin:0;text-align:center'>&#160;</p>
<p style='font:11pt Times New Roman;margin:0;text-align:center'>Date of Report (date of earliest event reported): &#160;<b><ix:nonNumeric name='dei:DocumentPeriodEndDate' contextRef='D221025' format='ixt:datemonthdayyearen'>October 25, 2022</ix:nonNumeric></b></p>
<p style='font:11pt Times New Roman;margin:0;text-align:center'>&#160;</p>
<p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
<table style='border-collapse:collapse;width:100%'><tr><td colspan='5' valign='top' style='width:100%;padding-left:0.7pt;padding-right:0.7pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='font-size:14pt'><b><ix:nonNumeric name='dei:EntityRegistrantName' contextRef='D221025' escape='true'>UTAH MEDICAL PRODUCTS, INC.</ix:nonNumeric></b></span></p>
</td></tr>
<tr><td colspan='5' valign='top' style='width:100%;padding-left:0.7pt;padding-right:0.7pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>(Exact name of registrant as specified in its charter)</p>
</td></tr>
<tr><td valign='top' style='width:31.62%;padding-left:0.7pt;padding-right:0.7pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:2.6%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:31.6%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:2.58%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:31.6%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr><td valign='top' style='width:31.62%;padding-left:0.7pt;padding-right:0.7pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'><b><ix:nonNumeric name='dei:EntityIncorporationStateCountryCode' contextRef='D221025' format='ixt-sec:stateprovnameen'>Utah</ix:nonNumeric></b></p>
</td><td valign='top' style='width:2.6%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:31.6%'><p style='font:10pt Times New Roman;margin:0;text-align:center'><b><ix:nonNumeric name='dei:EntityFileNumber' contextRef='D221025' escape='true'>000-12575</ix:nonNumeric></b></p>
</td><td valign='top' style='width:2.58%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:31.6%'><p style='font:10pt Times New Roman;margin:0;text-align:center'><b><ix:nonNumeric name='dei:EntityTaxIdentificationNumber' contextRef='D221025' escape='true'>87-0342734</ix:nonNumeric></b></p>
</td></tr>
<tr><td valign='top' style='width:31.62%;padding-left:0.7pt;padding-right:0.7pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>(State or other jurisdiction of</p>
</td><td valign='top' style='width:2.6%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:31.6%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>(Commission File Number)</p>
</td><td valign='top' style='width:2.58%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:31.6%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>(IRS Employer</p>
</td></tr>
<tr><td valign='top' style='width:31.62%;padding-left:0.7pt;padding-right:0.7pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>incorporation or organization)</p>
</td><td valign='top' style='width:2.6%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:31.6%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:2.58%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:31.6%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Identification No.)</p>
</td></tr>
<tr><td valign='top' style='width:31.62%;padding-left:0.7pt;padding-right:0.7pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:2.6%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:31.6%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:2.58%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:31.6%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr><td colspan='3' valign='top' style='width:65.82%;padding-left:0.7pt;padding-right:0.7pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'><b><ix:nonNumeric name='dei:EntityAddressAddressLine1' contextRef='D221025' escape='true'>7043 South 300 West</ix:nonNumeric></b></p>
</td><td valign='top' style='width:2.58%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:31.6%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr><td colspan='3' valign='top' style='width:65.82%;padding-left:0.7pt;padding-right:0.7pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'><b><ix:nonNumeric name='dei:EntityAddressCityOrTown' contextRef='D221025' escape='true'>Midvale</ix:nonNumeric>, <ix:nonNumeric name='dei:EntityAddressStateOrProvince' contextRef='D221025' format='ixt-sec:stateprovnameen'>Utah</ix:nonNumeric> </b></p>
</td><td valign='top' style='width:2.58%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:31.6%'><p style='font:10pt Times New Roman;margin:0;text-align:center'><b><ix:nonNumeric name='dei:EntityAddressPostalZipCode' contextRef='D221025' escape='true'>84047</ix:nonNumeric></b></p>
</td></tr>
<tr><td colspan='3' valign='top' style='width:65.82%;padding-left:0.7pt;padding-right:0.7pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>(Address of principal executive offices)</p>
</td><td valign='top' style='width:2.58%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:31.6%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>(Zip code)</p>
</td></tr>
<tr><td colspan='3' valign='top' style='width:65.82%;padding-left:0.7pt;padding-right:0.7pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:2.58%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:31.6%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr><td colspan='3' valign='top' style='width:65.82%;padding-left:0.7pt;padding-right:0.7pt'><p style='font:10pt Times New Roman;margin:0'>Registrant&#8217;s telephone number, including area code: &#160;</p>
</td><td valign='top' style='width:2.58%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:31.6%'><p style='font:10pt Times New Roman;margin:0;text-align:center'><b>Phone: (<ix:nonNumeric name='dei:CityAreaCode' contextRef='D221025' escape='true'>801</ix:nonNumeric>) <ix:nonNumeric name='dei:LocalPhoneNumber' contextRef='D221025' escape='true'>566-1200</ix:nonNumeric></b></p>
</td></tr>
<tr><td colspan='3' valign='top' style='width:65.82%;padding-left:0.7pt;padding-right:0.7pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:2.58%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:31.6%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr><td colspan='5' valign='top' style='width:100%;padding-left:0.7pt;padding-right:0.7pt'><p style='font:12pt Times New Roman;margin:0;text-align:center'><b>n/a</b></p>
</td></tr>
<tr><td colspan='5' valign='top' style='width:100%;padding-left:0.7pt;padding-right:0.7pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>(Former name or former address, if changed since last report)</p>
</td></tr>
</table>
<p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0;text-align:justify'>Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>
<p style='font:10pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
<table style='border-collapse:collapse;width:100%'><tr><td valign='top' style='width:5.86%'><p style='font:10pt Times New Roman;margin:0;text-align:justify'><ix:nonNumeric name='dei:WrittenCommunications' contextRef='D221025' format='ixt-sec:boolballotbox'>&#9744;</ix:nonNumeric></p>
</td><td valign='top' style='width:94.14%'><p style='font:10pt Times New Roman;margin:0;text-align:justify'>Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p>
</td></tr>
<tr><td valign='top' style='width:5.86%'><p style='font:10pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td><td valign='top' style='width:94.14%'><p style='font:10pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td></tr>
<tr><td valign='top' style='width:5.86%'><p style='font:10pt Times New Roman;margin:0;text-align:justify'><ix:nonNumeric name='dei:SolicitingMaterial' contextRef='D221025' format='ixt-sec:boolballotbox'>&#9744;</ix:nonNumeric></p>
</td><td valign='top' style='width:94.14%'><p style='font:10pt Times New Roman;margin:0;text-align:justify'>Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p>
</td></tr>
<tr><td valign='top' style='width:5.86%'><p style='font:10pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td><td valign='top' style='width:94.14%'><p style='font:10pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td></tr>
<tr><td valign='top' style='width:5.86%'><p style='font:10pt Times New Roman;margin:0;text-align:justify'><ix:nonNumeric name='dei:PreCommencementTenderOffer' contextRef='D221025' format='ixt-sec:boolballotbox'>&#9744;</ix:nonNumeric></p>
</td><td valign='top' style='width:94.14%'><p style='font:10pt Times New Roman;margin:0;text-align:justify'>Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p>
</td></tr>
<tr><td valign='top' style='width:5.86%'><p style='font:10pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td><td valign='top' style='width:94.14%'><p style='font:10pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td></tr>
<tr><td valign='top' style='width:5.86%'><p style='font:10pt Times New Roman;margin:0;text-align:justify'><ix:nonNumeric name='dei:PreCommencementIssuerTenderOffer' contextRef='D221025' format='ixt-sec:boolballotbox'>&#9744;</ix:nonNumeric></p>
</td><td valign='top' style='width:94.14%'><p style='font:10pt Times New Roman;margin:0;text-align:justify'>Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p>
</td></tr>
<tr><td valign='top' style='width:5.86%'><p style='font:10pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td><td valign='top' style='width:94.14%'><p style='font:10pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td></tr>
<tr><td colspan='2' valign='top' style='width:100%'><p style='font:10pt Times New Roman;margin:0;text-align:justify'>Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (Section 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (Section 240.12b-2 of this chapter).</p>
</td></tr>
<tr><td valign='top' style='width:5.86%'><p style='font:10pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td><td valign='top' style='width:94.14%'><p style='font:10pt Times New Roman;margin:0;text-align:right'>Emerging growth company <ix:nonNumeric name='dei:EntityEmergingGrowthCompany' contextRef='D221025' format='ixt-sec:boolballotbox'>&#9744;</ix:nonNumeric></p>
</td></tr>
<tr><td colspan='2' valign='top' style='width:100%'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td></tr>
<tr><td colspan='2' valign='top' style='width:100%'><p style='font:10pt Times New Roman;margin:0;text-align:justify'>If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <span style='font-family:Wingdings'><span style='font-family:Wingdings'>&#168;</span></span></p>
</td></tr>
</table>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><hr style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'/><p style='line-height:0;margin:0'></p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt Times New Roman;margin:0'><b>ITEM 2.02&#8212;RESULTS OF OPERATIONS AND FINANCIAL CONDITION</b></p>
<p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0;margin-left:61.2pt;text-align:justify'>Attached hereto as Exhibit 99.1 and incorporated by reference herein is financial information for Utah Medical Products, Inc. for the three and nine months ended September 30, 2022 and forward-looking statements relating to 2022 and beyond as presented in a press release dated October 25, 2022. &#160;</p>
<p style='font:10pt Times New Roman;margin:0;margin-left:72pt;text-align:justify'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0;margin-left:61.2pt;text-align:justify'>The information in this report (including Exhibit 99.1) is being furnished pursuant to Item 2.02 and shall not be deemed to be &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, (the &#8220;Exchange Act&#8221;) or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act.</p>
<p style='font:10pt Times New Roman;margin:0;margin-left:72pt;text-align:justify'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><b>ITEM 9.01&#8212;FINANCIAL STATEMENTS AND EXHIBITS</b></p>
<p style='font:10pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0;text-align:justify'>The following is filed as an exhibit to this report: &#160;</p>
<p style='font:10pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
<table style='border-collapse:collapse;width:100%'><tr><td valign='top' style='width:12.56%;padding-left:5.75pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'><b>Exhibit</b></p>
<p style='font:10pt Times New Roman;margin:0;text-align:center'><b>Number*</b></p>
</td><td valign='top' style='width:2.62%;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:69.22%;padding-left:5.75pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0;text-align:center'><b>Title of Document</b></p>
</td><td valign='top' style='width:2.62%;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:12.98%;padding-left:5.75pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0;text-align:center'><b>Location</b></p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:12.56%;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'><b>Item 99.1</b></p>
</td><td valign='top' style='background-color:#CCEEFF;width:2.62%;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:69.22%;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'><span style='color:#0000FF;border-bottom:1px solid #0000FF'><a href='utah_ex99z1.htm' style='text-decoration:none'>Financial information for Utah Medical Products, Inc. for the three and nine months ended September 30, 2022 and forward-looking statements relating to 2022 and beyond as presented in a press release dated October 25, 2022.</a></span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:2.62%;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:12.98%;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'>This filing</p>
</td></tr>
</table>
<p style='font:10pt Times New Roman;margin:0;text-indent:-18pt;margin-left:18pt;text-align:justify'>_______________________________________</p>
<p style='font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt;margin-left:18pt;text-align:justify'><kbd style='position:absolute;font:10pt Times New Roman;margin-left:-18pt'>*</kbd>All exhibits are numbered with the number preceding the decimal indicating the applicable SEC reference number in Item 601 and the number following the decimal indicating the sequence of the particular document. &#160;</p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><hr style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'/><p style='line-height:0;margin:0'></p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt Times New Roman;margin:0;text-align:center'><b>SIGNATURES</b></p>
<p style='font:10pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0;text-align:justify'>Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>
<p style='font:10pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
<table style='border-collapse:collapse;width:100%'><tr><td valign='top' style='width:55.84%'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td colspan='2' valign='top' style='width:44.16%'><p style='font:10pt Times New Roman;margin:0'><b>UTAH MEDICAL PRODUCTS, INC.</b></p>
</td></tr>
<tr><td valign='top' style='width:55.84%'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:4.74%'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:39.42%'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td></tr>
<tr><td valign='top' style='width:55.84%'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:4.74%'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:39.42%'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td></tr>
<tr><td valign='top' style='width:55.84%'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:4.74%'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:39.42%'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td></tr>
<tr><td valign='top' style='width:55.84%'><p style='font:10pt Times New Roman;margin:0'>Dated: October 25, 2022</p>
</td><td valign='top' style='width:4.74%'><p style='font:10pt Times New Roman;margin:0'>By:</p>
</td><td valign='top' style='width:39.42%;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0'>/s/ Kevin L. Cornwell</p>
</td></tr>
<tr><td valign='top' style='width:55.84%'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:4.74%'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:39.42%;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0'>Kevin L. Cornwell, <br/>Chief Executive Officer</p>
</td></tr>
</table>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/></div>
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>utah_ex99z1.htm
<DESCRIPTION>FINANCIAL INFORMATION FOR UTAH MEDICAL PRODUCTS, INC. FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2022 AND FORWARD-LOOKING STATEMENTS RELATING TO 2022 AND BEYOND AS PRESENTED IN A PRESS RELEASE DATED OCTOBER 25, 2022.
<TEXT>
<HTML>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2022 [PPXK5GW761L0VGS139PY]. www.edgarsuite.com -->
<HEAD>
</HEAD>
<BODY>
<DIV style=margin-left:72pt;width:468pt><P align=center style='font:10pt Times New Roman;margin:0'><B>EXHIBIT 99.1 </B></P>
<P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>UTMD Reports Financial Performance for Third Calendar Quarter and Nine Months 2022</B></P>
<TABLE style=border-collapse:collapse;width:100%><TR><TD valign=top style=width:50%><P style='font:10pt Times New Roman;margin:0'>Contact: Crystal Rios (801) 566-1200</P>
</TD><TD valign=top style=width:50%><P align=right style='font:10pt Times New Roman;margin:0'>October 25, 2022</P>
</TD></TR>
</TABLE>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>Salt Lake City, Utah &#8211;&nbsp;In the third calendar quarter (3Q) of 2022, despite significant cost inflation, supply chain disruption, litigation expenses and negative impact of a stronger U.S. Dollar on foreign currency sales, Utah Medical Products, Inc. (Nasdaq: UTMD) continued to achieve financial results which were better than those anticipated in its beginning of year projections. &nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>Currencies in this release are denoted as $ or USD = U.S. Dollars; AUD = Australia Dollars; &#163;&nbsp;or GBP = UK Pound Sterling; C$ or CAD = Canadian Dollars; and &#8364;&nbsp;or EUR = Euros. Currency amounts throughout this report are in thousands, except per share amounts and where noted. &nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Overview of Results</FONT></P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>The following is a summary comparison of 3Q and first nine months (9M) of calendar 2022 with 3Q and 9M 2021 income statement measures:</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE style=border-collapse:collapse;width:100%><TR><TD valign=top style=width:52.24%><P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:1.44%><P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:20.58%><P align=center style='font:10pt Times New Roman;margin:0'>3Q</P>
</TD><TD valign=top style=width:1.44%><P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:24.28%><P align=center style='font:10pt Times New Roman;margin:0'>9M</P>
</TD></TR>
<TR><TD valign=top style='width:52.24%;border-bottom:0.5pt solid #000000'><P style='font:10pt Times New Roman;margin:0'>2022 to 2021 Comparison</P>
</TD><TD valign=top style=width:1.44%><P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:20.58%;border-bottom:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>(July&#8211;September)</P>
</TD><TD valign=top style=width:1.44%><P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:24.28%;border-bottom:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>(January-September)</P>
</TD></TR>
<TR><TD valign=top style='background-color:#CCEEFF;width:52.24%;border-top:0.5pt solid #000000'><P style='font:10pt Times New Roman;margin:0'>Revenues (Sales):</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:1.44%><P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:20.58%;border-top:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>+ 3%</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:1.44%><P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:24.28%;border-top:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>+ 7%</P>
</TD></TR>
<TR><TD valign=top style=width:52.24%><P style='font:10pt Times New Roman;margin:0'>Gross Profit (GP):</P>
</TD><TD valign=top style=width:1.44%><P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:20.58%><P align=center style='font:10pt Times New Roman;margin:0'>+ 1%</P>
</TD><TD valign=top style=width:1.44%><P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:24.28%><P align=center style='font:10pt Times New Roman;margin:0'>+ 5%</P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:52.24%><P style='font:10pt Times New Roman;margin:0'>Operating Income (OI):</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:1.44%><P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:20.58%><P align=center style='font:10pt Times New Roman;margin:0'>+ 1%</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:1.44%><P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:24.28%><P align=center style='font:10pt Times New Roman;margin:0'>+ 7%</P>
</TD></TR>
<TR><TD valign=top style=width:52.24%><P style='font:10pt Times New Roman;margin:0'>Income Before Tax (EBT): </P>
</TD><TD valign=top style=width:1.44%><P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:20.58%><P align=center style='font:10pt Times New Roman;margin:0'>+ 4% </P>
</TD><TD valign=top style=width:1.44%><P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:24.28%><P align=center style='font:10pt Times New Roman;margin:0'>+ 9% </P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:52.24%><P style='font:10pt Times New Roman;margin:0'>Net Income (NI):</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:1.44%><P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:20.58%><P align=center style='font:10pt Times New Roman;margin:0'>+ 2%</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:1.44%><P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:24.28%><P align=center style='font:10pt Times New Roman;margin:0'>+ 12%</P>
</TD></TR>
<TR><TD valign=top style=width:52.24%><P style='font:10pt Times New Roman;margin:0'>Earnings Per Share (EPS):</P>
</TD><TD valign=top style=width:1.44%><P align=center style='font:10pt Times New Roman;margin:0'>&#160;&#160;</P>
</TD><TD valign=top style=width:20.58%><P align=center style='font:10pt Times New Roman;margin:0'>+ 2%</P>
</TD><TD valign=top style=width:1.44%><P align=center style='font:10pt Times New Roman;margin:0'>&#160;&#160;</P>
</TD><TD valign=top style=width:24.28%><P align=center style='font:10pt Times New Roman;margin:0'>+ 12%</P>
</TD></TR>
</TABLE>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>The above increases in NI and EPS according to U.S. Generally Accepted Accounting Principles (US GAAP) were affected by a long-term deferred tax liability (DTL) increase in 9M 2021 on the balance of Femcare identifiable intangible assets (IIA) due to a future change enacted during 2Q 2021 in UK income tax rates. As stockholders may remember, the DTL was initiated as of the 2011 acquisition of Femcare because the expense from amortizing Femcare IIA, most of which is occurring over a fifteen-year time span from the acquisition date, is not tax-deductible in the UK. According to US GAAP, the future tax impact of a change in DTL must be recognized in the quarter in which a tax law change is enacted. In 2Q 2021, a $390 increase in DTL over the remaining five amortization years occurred because in June 2021, UK parliament ratified the Finance Minister&#8217;s plan to increase the UK corporate income tax rate from 19% to 25% beginning on April 1, 2023. &nbsp;For clarity, the change affects the deferred taxes for IIA to be amortized after April 1, 2023 until fully amortized as of 1Q 2026.</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>UTMD management believes that the presentation of results excluding the unfavorable deferred tax liability adjustment to its 9M 2021 income tax provision provides meaningful supplemental information to both management and investors that is more clearly indicative of UTMD&#8217;s operating results. The non-US GAAP exclusion only affects Net Income and Earnings Per Share.</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>Excluding the 2Q 2021 deferred tax liability increase and resulting &#8220;one-time&#8221; tax provision increase due to the UK income tax rate change, the resulting non-US GAAP 9M NI and EPS changes follow:</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE style=border-collapse:collapse;width:100%><TR><TD valign=top style=width:77.24%><P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:22.76%><P align=center style='font:10pt Times New Roman;margin:0'>9M 2022 to 9M 2021</P>
</TD></TR>
<TR><TD valign=top style=width:77.24%><P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:22.76%;border-bottom:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>(January-September)</P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:77.24%><P style='font:10pt Times New Roman;margin:0'>NI (non-US GAAP):</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:22.76%;border-top:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>+ 8%</P>
</TD></TR>
<TR><TD valign=top style=width:77.24%><P style='font:10pt Times New Roman;margin:0'> EPS (non-US GAAP):</P>
</TD><TD valign=top style=width:22.76%><P align=center style='font:10pt Times New Roman;margin:0'>+ 8%</P>
</TD></TR>
</TABLE>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=center style='font:10pt Times New Roman;margin:0'>1</P>
<HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>In brief, the non-US GAAP changes in NI and EPS were more consistent with changes in OI and EBT.</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>Worldwide (WW) consolidated sales in all four major product categories were up in 3Q 2022 compared to 3Q 2021 despite a much stronger USD. The same was true for 9M 2022, except for gynecology category sales which were about 1% lower than in 9M 2021. &nbsp;Sales invoiced in foreign currencies represented 19% of total WW consolidated 3Q 2022 sales (when expressed in USD) and 24% of 9M 2022 total WW consolidated sales. WW consolidated USD sales in 3Q 2022, instead of being 3% higher, would have been 6% higher, and in 9M 2022, instead of being 7% higher, would have been 10% higher than the USD sales which would have resulted using the same foreign currency exchange (FX) rates as in the prior year&#8217;s same periods (&#8220;constant currency sales&#8221;). &nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>Profit margins in 3Q and 9M 2022 compared to 3Q and 9M 2021 follow:</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE style=border-collapse:collapse;width:100%><TR><TD valign=top style=width:40%><P style='font:10pt Times New Roman;margin:0;text-indent:7.1pt'>&nbsp;</P>
</TD><TD valign=top style=width:1.24%><P align=center style='font:10pt Times New Roman;margin:0;text-indent:7.1pt'>&nbsp;</P>
</TD><TD valign=top style='width:12%;border-bottom:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0;text-indent:7.1pt'>3Q 2022 </P>
<P align=center style='font:10pt Times New Roman;margin:0;text-indent:7.1pt'>(Jul &#8211;&nbsp;Sep)</P>
</TD><TD valign=top style=width:1.24%><P align=center style='font:10pt Times New Roman;margin:0;text-indent:7.1pt'>&nbsp;</P>
</TD><TD valign=top style='width:12%;border-bottom:0.5pt solid #000000;border-right:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0;text-indent:7.1pt'>3Q 2021</P>
<P align=center style='font:10pt Times New Roman;margin:0;text-indent:7.1pt'>(Jul &#8211;&nbsp;Sep)</P>
</TD><TD valign=top style='width:1.36%;border-right:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0;text-indent:7.1pt'>&nbsp;</P>
</TD><TD valign=top style='width:12%;border-left:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0;text-indent:7.1pt'>9M 2022</P>
<P align=center style='font:10pt Times New Roman;margin:0;text-indent:7.1pt'>(Jan &#8211;&nbsp;Sep)</P>
</TD><TD valign=top style=width:1.24%><P align=center style='font:10pt Times New Roman;margin:0;text-indent:7.1pt'>&nbsp;</P>
</TD><TD valign=top style='width:12%;border-bottom:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0;text-indent:7.1pt'>9M 2021</P>
<P align=center style='font:10pt Times New Roman;margin:0;text-indent:7.1pt'>(Jan &#8211;&nbsp;Sep)</P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:40%><P style='font:10pt Times New Roman;margin:0'>Gross Profit Margin (GP/ sales):</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:1.24%><P align=center style='font:10pt Times New Roman;margin:0;text-indent:7.1pt'>&nbsp;</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:12%;border-top:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0;text-indent:7.1pt'>63.2%</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:1.24%><P align=center style='font:10pt Times New Roman;margin:0;text-indent:7.1pt'>&nbsp;</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:12%;border-top:0.5pt solid #000000;border-right:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0;text-indent:7.1pt'>64.2% </P>
</TD><TD valign=top style='background-color:#CCEEFF;width:1.36%;border-right:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0;text-indent:7.1pt'>&nbsp;</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:12%;border-top:0.5pt solid #000000;border-left:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0;text-indent:7.1pt'>61.7%</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:1.24%><P align=center style='font:10pt Times New Roman;margin:0;text-indent:7.1pt'>&nbsp;</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:12%;border-top:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0;text-indent:7.1pt'>63.1%</P>
</TD></TR>
<TR><TD valign=top style=width:40%><P style='font:10pt Times New Roman;margin:0'>Operating Income Margin (OI/ sales):</P>
</TD><TD valign=top style=width:1.24%><P align=center style='font:10pt Times New Roman;margin:0;text-indent:7.1pt'>&nbsp;</P>
</TD><TD valign=top style=width:12%><P align=center style='font:10pt Times New Roman;margin:0;text-indent:7.1pt'>39.7%</P>
</TD><TD valign=top style=width:1.24%><P align=center style='font:10pt Times New Roman;margin:0;text-indent:7.1pt'>&nbsp;</P>
</TD><TD valign=top style='width:12%;border-right:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0;text-indent:7.1pt'>40.6%</P>
</TD><TD valign=top style='width:1.36%;border-right:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0;text-indent:7.1pt'>&nbsp;</P>
</TD><TD valign=top style='width:12%;border-left:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0;text-indent:7.1pt'>38.0%</P>
</TD><TD valign=top style=width:1.24%><P align=center style='font:10pt Times New Roman;margin:0;text-indent:7.1pt'>&nbsp;</P>
</TD><TD valign=top style=width:12%><P align=center style='font:10pt Times New Roman;margin:0;text-indent:7.1pt'>38.0%</P>
</TD></TR>
<TR><TD valign=top style='background-color:#CCEEFF;width:40%;border-bottom:0.5pt solid #000000'><P style='font:10pt Times New Roman;margin:0'>Net Income Margin &nbsp;(US GAAP)</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:1.24%><P align=center style='font:10pt Times New Roman;margin:0;text-indent:7.1pt'>&nbsp;</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:12%;border-bottom:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0;text-indent:7.1pt'>33.0%</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:1.24%><P align=center style='font:10pt Times New Roman;margin:0;text-indent:7.1pt'>&nbsp;</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:12%;border-bottom:0.5pt solid #000000;border-right:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0;text-indent:7.1pt'>33.5%</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:1.36%;border-right:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0;text-indent:7.1pt'>&nbsp;</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:12%;border-left:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0;text-indent:7.1pt'>30.8%</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:1.24%><P align=center style='font:10pt Times New Roman;margin:0;text-indent:7.1pt'>&nbsp;</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:12%;border-bottom:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0;text-indent:7.1pt'>29.5%</P>
</TD></TR>
<TR><TD valign=top style='width:40%;border-top:0.5pt solid #000000'><P style='font:10pt Times New Roman;margin:0'><I>Net Income Margin (Non-US GAAP, B4 DTL Adj):</I></P>
</TD><TD valign=top style=width:1.24%><P align=center style='font:10pt Times New Roman;margin:0;text-indent:7.1pt'>&nbsp;</P>
</TD><TD valign=top style='width:12%;border-top:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0;text-indent:7.1pt'><I>33.0% </I></P>
</TD><TD valign=top style=width:1.24%><P align=center style='font:10pt Times New Roman;margin:0;text-indent:7.1pt'>&nbsp;</P>
</TD><TD valign=top style='width:12%;border-top:0.5pt solid #000000;border-right:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0;text-indent:7.1pt'><I>33.5%</I></P>
</TD><TD valign=top style='width:1.36%;border-right:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0;text-indent:7.1pt'>&nbsp;</P>
</TD><TD valign=top style='width:12%;border-top:0.5pt solid #000000;border-left:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0;text-indent:7.1pt'><I>30.8%</I></P>
</TD><TD valign=top style=width:1.24%><P align=center style='font:10pt Times New Roman;margin:0;text-indent:7.1pt'>&nbsp;</P>
</TD><TD valign=top style='width:12%;border-top:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0;text-indent:7.1pt'><I>30.6%</I></P>
</TD></TR>
</TABLE>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>Note: &nbsp;The Net Income Margin is NI, after subtracting provisions for income taxes, divided by sales.</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>During 3Q 2022, the Company continued to realize substantial increases in manufacturing costs, highlighted by incoming freight on raw materials, which has doubled compared to 2021. &nbsp;Part of the large increase in freight costs is due to UTMD&#8217;s decision to purchase larger quantities of raw materials in order to hedge against continuing cost inflation, minimize risk of disruption from unreliable supplier performance and gain available quantity discounts. &nbsp;Thankfully, UTMD&#8217;s cash position supports this sort of longer-term decision; and so much for the &#8220;just-in-time&#8221; good manufacturing tenet of the past. </P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>Although UTMD has lost almost no production capacity in 2022 as a result of COVID-19 infections in its workforce, the effect of misguided government policies and spending during the pandemic, which caused limited willing workers, continues to linger. &nbsp;&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>Although profits margins generally have been squeezed, the same 38% operating income margin in 9M 2022 as in 9M 2021 suggests that management has been successful to date in responding to the challenge. In this instance, a stronger USD has helped by reducing foreign currency operating expenses in USD terms, including the GBP amortization of Identifiable Intangible Assets (IIA). The unfortunate increase in UTMD&#8217;s litigation costs, which are part of General and Administrative (G&amp;A) operating expenses, has perversely been offset by UTMD&#8217;s inability in 2022 to hire replacements for departed G&amp;A employees. </P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>UTMD&#8217;s September 30, 2022 Balance Sheet, in the absence of debt, continued to strengthen with total assets up $2.8 million from the end of 2021. Ending Cash and Investments were $69.5 million on September 30, 2022 compared to $61.0 million on December 31, 2021, after paying $2.1 million in cash dividends to stockholders and purchasing $2.5 million in UTMD stock during 9M 2022. &nbsp;UTMD&#8217;s cash balance increased $2.35/ outstanding share at September 30, 2022 from the end of 2021 with a 12% increase in Net Income, while the stock price declined $14.69/ share. Stockholders&#8217; Equity (SE) increased $1.0 million in the nine-month period from December 31, 2021 despite the fact that $4.6 million in dividends and share repurchases reduced SE. &nbsp;&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>Foreign currency exchange (FX) rates for Balance Sheet purposes are the applicable rates at the end of each reporting period. The FX rates from the applicable foreign currency to USD for assets and liabilities at the end of 3Q 2022 compared to the end of calendar year 2021 and the end of 3Q 2021 follow:</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE style=border-collapse:collapse;width:100%><TR><TD valign=top style=width:20.04%><P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:13.46%><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>9-30-22</FONT></P>
</TD><TD valign=top style=width:14.9%><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>12-31-21</FONT></P>
</TD><TD valign=top style='width:17.2%;border-right:1.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Change</FONT></P>
</TD><TD valign=top style='width:14.9%;border-left:1.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>9-30-21</FONT></P>
</TD><TD valign=top style=width:19.5%><P align=center style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Change</FONT></P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:20.04%><P style='font:10pt Times New Roman;margin:0'>GBP</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:13.46%><P align=right style='font:10pt Times New Roman;margin:0'>1.11303</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:14.9%><P align=right style='font:10pt Times New Roman;margin:0'>1.35358</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:17.2%;border-right:1.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>(17.8%)</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:14.9%;border-left:1.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>1.34676</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:19.5%><P align=center style='font:10pt Times New Roman;margin:0'>(17.4%)</P>
</TD></TR>
<TR><TD valign=top style=width:20.04%><P style='font:10pt Times New Roman;margin:0'>EUR</P>
</TD><TD valign=top style=width:13.46%><P align=right style='font:10pt Times New Roman;margin:0'>0.97878</P>
</TD><TD valign=top style=width:14.9%><P align=right style='font:10pt Times New Roman;margin:0'>1.13765</P>
</TD><TD valign=top style='width:17.2%;border-right:1.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>(14.0%)</P>
</TD><TD valign=top style='width:14.9%;border-left:1.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>1.15770</P>
</TD><TD valign=top style=width:19.5%><P align=center style='font:10pt Times New Roman;margin:0'>(15.5%)</P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:20.04%><P style='font:10pt Times New Roman;margin:0'>AUD</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:13.46%><P align=right style='font:10pt Times New Roman;margin:0'>0.64366</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:14.9%><P align=right style='font:10pt Times New Roman;margin:0'>0.72678</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:17.2%;border-right:1.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>(11.4%)</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:14.9%;border-left:1.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>0.72284</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:19.5%><P align=center style='font:10pt Times New Roman;margin:0'>(11.0%)</P>
</TD></TR>
<TR><TD valign=top style=width:20.04%><P style='font:10pt Times New Roman;margin:0'>CAD</P>
</TD><TD valign=top style=width:13.46%><P align=right style='font:10pt Times New Roman;margin:0'>0.72722</P>
</TD><TD valign=top style=width:14.9%><P align=right style='font:10pt Times New Roman;margin:0'>0.79016</P>
</TD><TD valign=top style='width:17.2%;border-right:1.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>( &nbsp;8.0%)</P>
</TD><TD valign=top style='width:14.9%;border-left:1.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>0.78908</P>
</TD><TD valign=top style=width:19.5%><P align=center style='font:10pt Times New Roman;margin:0'>( &nbsp;7.8%)</P>
</TD></TR>
</TABLE>
<HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Revenues (sales)</FONT> -<FONT style='border-bottom:1px solid #000000'>3Q 2022</FONT></P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>Total WW UTMD consolidated 3Q 2022 sales were $383 (+3.0%) higher than in 3Q 2021. WW constant currency sales were $737 (+5.9%) higher. U.S. domestic sales were 11.2% higher (obviously without any FX impact), and outside the U.S. (OUS) sales were 10.0% lower. Without the harm of a stronger USD in converting foreign currency sales, OUS sales were just 2.7% lower. Because of the relatively short span of time, results for any given three month period in comparison with a previous three month period may not be indicative of comparative results for the year as a whole. </P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>Domestic U.S. sales in 3Q 2022 were $8,615 compared to $7,749 in 3Q 2021. &nbsp;Domestic sales are invoiced in USD and not subject to FX rate fluctuations. The components of domestic sales include 1) &#8220;direct other device sales&#8221; of UTMD&#8217;s medical devices to user facilities (and med/surg stocking distributors for hospitals), excluding Filshie device sales, 2) &#8220;OEM sales&#8221; of components and other products manufactured by UTMD for other medical device and non-medical device companies, and 3) &#8220;direct Filshie device sales&#8221;. UTMD separates Filshie device sales from other medical device sales direct to medical facilities because of their significance, and the acquisition history. Direct other device sales, representing 47% of total domestic sales, were $342 (+9.2%) higher in 3Q 2022 than in 3Q 2021. OEM sales, representing 35% of total domestic sales, were $591 (+24.0%) higher. Direct Filshie device sales, representing 17% of total domestic sales, were $68 (4.4%) lower in 3Q 2022 compared to 3Q 2021. </P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>OUS sales in 3Q 2022 were 10.0% lower at $4,340 compared to $4,823 in 3Q 2021. The decrease in USD-denominated OUS sales was leveraged as a result of a stronger USD which subtracted $354 from OUS sales that were invoiced in GBP, EUR, AUD and CAD foreign currencies in constant currency terms. &nbsp;&#8220;Constant currency&#8221; sales means exchanging foreign currency sales into USD-denominated sales at the same FX rate as was in the previous period of time being compared. FX rates for income statement purposes are transaction-weighted averages. The weighted-average FX rates from the applicable foreign currency to USD during 3Q 2022 and 3Q 2021 for revenue purposes follow:</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE style=border-collapse:collapse;width:100%><TR><TD valign=top style=width:60%><P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:1%><P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:10%;border-bottom:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>3Q 2022</P>
</TD><TD valign=top style=width:1%><P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:10%;border-bottom:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>3Q 2021</P>
</TD><TD valign=top style=width:1%><P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:10%;border-bottom:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>Change</P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:67%><P style='font:10pt Times New Roman;margin:0'>GBP</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:1%><P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:10%;border-top:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>1.1760</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:1%><P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:10%;border-top:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>1.3785</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:1%><P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:10%;border-top:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>(14.7%)</P>
</TD></TR>
<TR><TD valign=top style=width:67%><P style='font:10pt Times New Roman;margin:0'>EUR</P>
</TD><TD valign=top style=width:1%><P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:10%><P align=center style='font:10pt Times New Roman;margin:0'>1.0040</P>
</TD><TD valign=top style=width:1%><P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:10%><P align=center style='font:10pt Times New Roman;margin:0'>1.1793</P>
</TD><TD valign=top style=width:1%><P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:10%><P align=center style='font:10pt Times New Roman;margin:0'>(14.9%)</P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:67%><P style='font:10pt Times New Roman;margin:0'>AUD</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:1%><P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:10%><P align=center style='font:10pt Times New Roman;margin:0'>0.6828</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:1%><P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:10%><P align=center style='font:10pt Times New Roman;margin:0'>0.7348</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:1%><P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:10%><P align=center style='font:10pt Times New Roman;margin:0'>( 7.1%)</P>
</TD></TR>
<TR><TD valign=top style=width:67%><P style='font:10pt Times New Roman;margin:0'>CAD</P>
</TD><TD valign=top style=width:1%><P style='font:10pt Times New Roman;margin:0'>&#160;&#160;</P>
</TD><TD valign=top style=width:10%><P align=center style='font:10pt Times New Roman;margin:0'>0.7663</P>
</TD><TD valign=top style=width:1%><P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:10%><P align=center style='font:10pt Times New Roman;margin:0'>0.7941</P>
</TD><TD valign=top style=width:1%><P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:10%><P align=center style='font:10pt Times New Roman;margin:0'>( 3.5%)</P>
</TD></TR>
</TABLE>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>The weighted average unfavorable impact on 3Q 2022 foreign currency OUS sales was 12.4%, reducing reported USD sales by $354 relative to the same foreign currency sales in 3Q 2021. &nbsp;In constant currency terms, foreign currency sales in 3Q 2022 were 2.7% lower than in 3Q 2021. The portion of OUS sales invoiced in foreign currencies in USD terms were 19.3% of total consolidated 3Q 2022 sales compared to 26.7% in 3Q 2021. &nbsp;&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>OUS sales invoiced in foreign currencies are due to direct end-user sales in Ireland, the UK, France, Canada, Australia and New Zealand, and to shipments to OUS distributors of products manufactured by UTMD subsidiaries in Ireland and the UK. &nbsp;Export sales from the U.S. to OUS distributors are invoiced in USD. &nbsp;Direct to end-user foreign currency OUS 3Q 2022 sales in USD terms were 4.9% lower in Ireland, 16.2% lower in Canada, 28.1% lower in France, 14.8% lower in AUS/NZ and 1.3% higher in the UK than in 3Q 2021. Sales to OUS distributors/ international OEM customers were 9.3% lower in 3Q 2022 than in 3Q 2021. </P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Sales</FONT> -<FONT style='border-bottom:1px solid #000000'>9M 2022</FONT></P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>Total consolidated 9M 2022 UTMD WW consolidated sales were $2,567 (+7.1%) higher than in 9M 2021. Constant currency sales were $3,529 (+9.8%) higher than in 9M 2021. U.S. domestic sales were 8.3% higher and OUS sales were 5.1% higher. Without the harm of a stronger USD in converting foreign currency sales, OUS sales were 12.2% higher. &nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>Domestic U.S. sales in 9M 2022 were $24,429 compared to $22,555 in 9M 2021. &nbsp;Direct other device sales, representing 49% of total domestic sales, were $1,202 (+11.1%) higher in 9M 2022 than in 9M 2021. OEM sales, representing 35% of total domestic sales, were $1,358 (+19.2%) higher. Direct Filshie device sales, representing 16% of total domestic sales, were $685 (14.8%) lower in 9M 2022 compared to 9M 2021. </P>
<HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<P style='font:10pt Times New Roman;margin:0'>OUS sales in 9M 2022 were 5.1% higher at $14,278 compared to $13,585 in 9M 2021. The increase in USD-denominated OUS sales was diminished as a result of a stronger USD which subtracted $962 from OUS sales that were invoiced in GBP, EUR, AUD and CAD foreign currencies (in constant currency terms). &nbsp;FX rates for income statement purposes are transaction-weighted averages. The weighted-average FX rates from the applicable foreign currency to USD during 9M 2022 and 9M 2021 for revenue purposes follow:</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE style=border-collapse:collapse;width:100%><TR><TD valign=top style=width:66.94%><P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:1.06%><P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:9.94%;border-bottom:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>9M 2022</P>
</TD><TD valign=top style=width:1.06%><P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:9.94%;border-bottom:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>9M 2021</P>
</TD><TD valign=top style=width:1.06%><P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:9.96%;border-bottom:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>Change</P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:66.94%><P style='font:10pt Times New Roman;margin:0'>GBP</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:1.06%><P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:9.94%;border-top:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>1.2488</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:1.06%><P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:9.94%;border-top:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>1.3860</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:1.06%><P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:9.96%;border-top:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>( &nbsp;9.9%)</P>
</TD></TR>
<TR><TD valign=top style=width:66.94%><P style='font:10pt Times New Roman;margin:0'>EUR</P>
</TD><TD valign=top style=width:1.06%><P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:9.94%><P align=center style='font:10pt Times New Roman;margin:0'>1.0672</P>
</TD><TD valign=top style=width:1.06%><P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:9.94%><P align=center style='font:10pt Times New Roman;margin:0'>1.1957</P>
</TD><TD valign=top style=width:1.06%><P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:9.96%><P align=center style='font:10pt Times New Roman;margin:0'>(10.7%)</P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:66.94%><P style='font:10pt Times New Roman;margin:0'>AUD</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:1.06%><P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:9.94%><P align=center style='font:10pt Times New Roman;margin:0'>0.7058</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:1.06%><P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:9.94%><P align=center style='font:10pt Times New Roman;margin:0'>0.7584</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:1.06%><P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:9.96%><P align=center style='font:10pt Times New Roman;margin:0'>( &nbsp;6.9%)</P>
</TD></TR>
<TR><TD valign=top style=width:66.94%><P style='font:10pt Times New Roman;margin:0'>CAD</P>
</TD><TD valign=top style=width:1.06%><P style='font:10pt Times New Roman;margin:0'>&#160;&#160;</P>
</TD><TD valign=top style=width:9.94%><P align=center style='font:10pt Times New Roman;margin:0'>0.7797</P>
</TD><TD valign=top style=width:1.06%><P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:9.94%><P align=center style='font:10pt Times New Roman;margin:0'>0.7985</P>
</TD><TD valign=top style=width:1.06%><P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:9.96%><P align=center style='font:10pt Times New Roman;margin:0'>( &nbsp;2.3%)</P>
</TD></TR>
</TABLE>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>The weighted-average unfavorable impact on 9M 2022 foreign currency OUS sales was 9.4%, reducing reported USD sales by $962 relative to the same foreign currency sales in 9M 2021. &nbsp;In constant currency terms, OUS sales in 9M 2022 were 9.8% higher than in 9M 2021. The portion of OUS sales invoiced in foreign currencies in USD terms was 23.9% of total consolidated 9M 2022 sales compared to 27.0% in 9M 2021. Direct to end-user foreign currency OUS 9M 2022 sales in USD terms were 1.9% higher in Ireland, 10.9% lower in Canada, 11.2% lower in France, 14.4% higher in the UK and 23.5% lower in AUS/NZ. Sales to OUS distributors/OEM customers were 12.0% higher in 9M 2022 than in 9M 2021. </P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Gross Profit (GP)</FONT> </P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>GP results from subtracting the costs of manufacturing, quality assurance and receiving materials from suppliers from revenues. UTMD&#8217;s GP was $113 (+1.4%) higher in 3Q 2022 than in 3Q 2021, and $1,065 (+4.7%) higher in 9M 2022 than in 9M 2021. The percentage increases in GP were less than the percentage increases in revenues, however, which resulted in lower GPMs in the table above. UTMD does not have long-term fixed price agreements. Near the end of 2021, UTMD generally increased product prices across-the-board by 6.5%. With the exception of OEM devices unique to specific customers, UTMD has not increased product prices further in 2022, resisting additional increases in order to not participate in helping cause systemic inflation. However, UTMD retains the ability to raise prices on its specialized devices if manufacturing costs continue to increase faster than sales. &nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>Variable manufacturing costs, including wages, raw materials and freight, all increased by double-digit percentages during 9M 2022, much more rapidly than UTMD&#8217;s price increases. Fixed costs were diluted by higher sales. Over time, management expects that some of the 2022 cost increases will prove transient, and to be able to adjust GPM performance back to UTMD&#8217;s more typical GPMs of the past. </P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Operating Income (OI)</FONT> </P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>OI results from subtracting Operating Expenses (OE) from GP. &nbsp;OI in 3Q 2022 was $5,141 compared to $5,098 in 3Q 2021, an increase of 0.8%; and was $14,720 in 9M 2022 compared to $13,750 in 9M 2021, an increase of 7.1%. &nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>OE are comprised of Sales and Marketing (S&amp;M) expenses, General and Administrative (G&amp;A) expenses and Product Development (R&amp;D) expenses. The following table summarizes OE in 3Q and 9M 2022 compared to the same periods in 2021 by OE category:</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE style=border-collapse:collapse;width:100%><TR><TD valign=bottom style=width:12.62%><P style='font:10pt Times New Roman;margin:0'>OE <BR><FONT style='border-bottom:1px solid #000000'>Category</FONT></P>
</TD><TD valign=bottom style=width:11.44%><P align=center style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>3Q 2022</FONT></P>
</TD><TD valign=bottom style='width:9.28%;border-right:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>% of <BR><FONT style='border-bottom:1px solid #000000'>sales</FONT></P>
</TD><TD valign=bottom style='width:11.12%;border-left:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>3Q 2021</FONT></P>
</TD><TD valign=bottom style='width:11.1%;border-right:1.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>% of <BR><FONT style='border-bottom:1px solid #000000'>sales</FONT></P>
</TD><TD valign=bottom style='width:11.12%;border-left:1.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>9M 2022</FONT></P>
</TD><TD valign=bottom style='width:11.1%;border-right:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>% of <BR><FONT style='border-bottom:1px solid #000000'>sales</FONT></P>
</TD><TD valign=bottom style='width:11.12%;border-left:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>9M 2021</FONT></P>
</TD><TD valign=bottom style=width:11.08%><P align=center style='font:10pt Times New Roman;margin:0'>% of <BR><FONT style='border-bottom:1px solid #000000'>sales</FONT></P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:12.62%><P style='font:10pt Times New Roman;margin:0'>S&amp;M:</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:11.44%><P align=center style='font:10pt Times New Roman;margin:0'>$ 373</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:9.28%;border-right:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'> &nbsp;2.9</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:11.12%;border-left:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>$ 324</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:11.1%;border-right:1.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'> &nbsp;2.6</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:11.12%;border-left:1.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>$ 1,066</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:11.1%;border-right:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'> &nbsp;2.7</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:11.12%;border-left:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>$ 1,071</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:11.08%><P align=center style='font:10pt Times New Roman;margin:0'> &nbsp;3.0</P>
</TD></TR>
<TR><TD valign=top style=width:12.62%><P style='font:10pt Times New Roman;margin:0'>G&amp;A:</P>
</TD><TD valign=top style=width:11.44%><P align=center style='font:10pt Times New Roman;margin:0'>2,560</P>
</TD><TD valign=top style='width:9.28%;border-right:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>19.8</P>
</TD><TD valign=top style='width:11.12%;border-left:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>2,524</P>
</TD><TD valign=top style='width:11.1%;border-right:1.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>20.1</P>
</TD><TD valign=top style='width:11.12%;border-left:1.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'> &nbsp;&nbsp;7,713</P>
</TD><TD valign=top style='width:11.1%;border-right:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>19.9</P>
</TD><TD valign=top style='width:11.12%;border-left:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'> &nbsp;&nbsp;7,598</P>
</TD><TD valign=top style=width:11.08%><P align=center style='font:10pt Times New Roman;margin:0'>21.0</P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:12.62%><P style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>R&amp;D:</FONT></P>
</TD><TD valign=top style=background-color:#CCEEFF;width:11.44%><P align=center style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp;112</FONT></P>
</TD><TD valign=top style='background-color:#CCEEFF;width:9.28%;border-right:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;0.8</FONT></P>
</TD><TD valign=top style='background-color:#CCEEFF;width:11.12%;border-left:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp;126</FONT></P>
</TD><TD valign=top style='background-color:#CCEEFF;width:11.1%;border-right:1.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;1.0</FONT></P>
</TD><TD valign=top style='background-color:#CCEEFF;width:11.12%;border-left:1.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;370</FONT></P>
</TD><TD valign=top style='background-color:#CCEEFF;width:11.1%;border-right:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;1.0</FONT></P>
</TD><TD valign=top style='background-color:#CCEEFF;width:11.12%;border-left:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp;&nbsp;&nbsp;385</FONT></P>
</TD><TD valign=top style=background-color:#CCEEFF;width:11.08%><P align=center style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;1.1</FONT></P>
</TD></TR>
<TR><TD valign=top style=width:12.62%><P style='font:10pt Times New Roman;margin:0'>Total OE:</P>
</TD><TD valign=top style=width:11.44%><P align=center style='font:10pt Times New Roman;margin:0'>3,045</P>
</TD><TD valign=top style='width:9.28%;border-right:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>23.5</P>
</TD><TD valign=top style='width:11.12%;border-left:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>2,974</P>
</TD><TD valign=top style='width:11.1%;border-right:1.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>23.7</P>
</TD><TD valign=top style='width:11.12%;border-left:1.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'> &nbsp;&nbsp;9,149</P>
</TD><TD valign=top style='width:11.1%;border-right:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>23.6</P>
</TD><TD valign=top style='width:11.12%;border-left:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'> &nbsp;9,054</P>
</TD><TD valign=top style=width:11.08%><P align=center style='font:10pt Times New Roman;margin:0'>25.1</P>
</TD></TR>
</TABLE>
<HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>Although a stronger USD helped reduce consolidated USD sales in 2022, it also helped reduce the USD-denominated OE of UTMD&#8217;s foreign subsidiaries by $130 in 3Q 2022 and $267 in 9M 2022. The following table summarizes &#8220;constant currency&#8221; OE in 3Q and 9M 2022 compared to the same periods in 2021 by OE category:</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE style=border-collapse:collapse;width:100%><TR><TD valign=bottom style=width:12.64%><P style='font:10pt Times New Roman;margin:0'>OE <BR><FONT style='border-bottom:1px solid #000000'>Category</FONT></P>
</TD><TD valign=bottom style=width:11.46%><P align=center style='font:10pt Times New Roman;margin:0'>3Q 2022 <FONT style='border-bottom:1px solid #000000'>const FX</FONT></P>
</TD><TD valign=bottom style='width:9.26%;border-right:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style='width:11.14%;border-left:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>3Q 2021</FONT></P>
</TD><TD valign=bottom style='width:11.08%;border-right:1.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style='width:11.14%;border-left:1.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>9M 2022 <FONT style='border-bottom:1px solid #000000'>const FX</FONT></P>
</TD><TD valign=bottom style='width:11.08%;border-right:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style='width:11.14%;border-left:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>9M 2021</FONT></P>
</TD><TD valign=bottom style=width:11.08%><P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:12.64%><P style='font:10pt Times New Roman;margin:0'>S&amp;M:</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:11.46%><P align=center style='font:10pt Times New Roman;margin:0'>$ 383</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:9.26%;border-right:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:11.14%;border-left:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>$ 324</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:11.08%;border-right:1.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:11.14%;border-left:1.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>$ 1,090</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:11.08%;border-right:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:11.14%;border-left:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>$ 1,071</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:11.08%><P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:12.64%><P style='font:10pt Times New Roman;margin:0'>G&amp;A:</P>
</TD><TD valign=top style=width:11.46%><P align=center style='font:10pt Times New Roman;margin:0'>2,680</P>
</TD><TD valign=top style='width:9.26%;border-right:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:11.14%;border-left:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>2,524</P>
</TD><TD valign=top style='width:11.08%;border-right:1.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:11.14%;border-left:1.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'> &nbsp;&nbsp;7,956</P>
</TD><TD valign=top style='width:11.08%;border-right:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:11.14%;border-left:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'> &nbsp;&nbsp;7,598</P>
</TD><TD valign=top style=width:11.08%><P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:12.64%><P style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>R&amp;D:</FONT></P>
</TD><TD valign=top style=background-color:#CCEEFF;width:11.46%><P align=center style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp;112</FONT></P>
</TD><TD valign=top style='background-color:#CCEEFF;width:9.26%;border-right:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:11.14%;border-left:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp;126</FONT></P>
</TD><TD valign=top style='background-color:#CCEEFF;width:11.08%;border-right:1.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:11.14%;border-left:1.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp;&nbsp;&nbsp;370</FONT></P>
</TD><TD valign=top style='background-color:#CCEEFF;width:11.08%;border-right:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:11.14%;border-left:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;385</FONT></P>
</TD><TD valign=top style=background-color:#CCEEFF;width:11.08%><P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:12.64%><P style='font:10pt Times New Roman;margin:0'>Total OE:</P>
</TD><TD valign=top style=width:11.46%><P align=center style='font:10pt Times New Roman;margin:0'>3,175</P>
</TD><TD valign=top style='width:9.26%;border-right:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:11.14%;border-left:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>2,974</P>
</TD><TD valign=top style='width:11.08%;border-right:1.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:11.14%;border-left:1.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'> &nbsp;&nbsp;9,416</P>
</TD><TD valign=top style='width:11.08%;border-right:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:11.14%;border-left:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'> &nbsp;9,054</P>
</TD><TD valign=top style=width:11.08%><P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
</TABLE>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>The change in FX rates reduced USD-denominated 3Q 2022 OUS S&amp;M expense by $10, and 9M 2022 OUS S&amp;M expense by $24. </P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>A division of G&amp;A expenses by location follows. G&amp;A expenses include non-cash expenses from the amortization of IIA associated with the Filshie Clip System, which is also separated out below: &nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE style=border-collapse:collapse;width:100%><TR><TD valign=bottom style=width:19.96%><P style='font:10pt Times New Roman;margin:0'>G&amp;A Exp </P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Category</FONT></P>
</TD><TD valign=bottom style=width:12.48%><P align=center style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>3Q 2022</FONT></P>
</TD><TD valign=bottom style='width:8.32%;border-right:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>% of <FONT style='border-bottom:1px solid #000000'>sales</FONT></P>
</TD><TD valign=bottom style='width:12.1%;border-left:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>3Q 2021</FONT></P>
</TD><TD valign=bottom style='width:7.64%;border-right:1.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>% of <FONT style='border-bottom:1px solid #000000'>sales</FONT></P>
</TD><TD valign=bottom style='width:12.1%;border-left:1.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>9M 2022</FONT></P>
</TD><TD valign=bottom style='width:7.64%;border-right:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>% of <FONT style='border-bottom:1px solid #000000'>sales</FONT></P>
</TD><TD valign=bottom style='width:12.1%;border-left:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>9M 2021</FONT></P>
</TD><TD valign=bottom style=width:7.64%><P align=center style='font:10pt Times New Roman;margin:0'>% of <FONT style='border-bottom:1px solid #000000'>sales</FONT></P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:19.96%><P style='font:10pt Times New Roman;margin:0'>IIA Amort- UK:</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:12.48%><P align=center style='font:10pt Times New Roman;margin:0'>$ 467</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:8.32%;border-right:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'> 3.6</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:12.1%;border-left:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'> $ 548</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:7.64%;border-right:1.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'> &nbsp;4.4</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:12.1%;border-left:1.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>$1,497</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:7.64%;border-right:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'> &nbsp;3.9</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:12.1%;border-left:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>$1,654</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:7.64%><P align=center style='font:10pt Times New Roman;margin:0'> &nbsp;4.6</P>
</TD></TR>
<TR><TD valign=top style=width:19.96%><P style='font:10pt Times New Roman;margin:0'>IIA Amort&#8211; CSI:</P>
</TD><TD valign=top style=width:12.48%><P align=center style='font:10pt Times New Roman;margin:0'>1,105</P>
</TD><TD valign=top style='width:8.32%;border-right:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>8.5</P>
</TD><TD valign=top style='width:12.1%;border-left:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>1,105</P>
</TD><TD valign=top style='width:7.64%;border-right:1.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'> &nbsp;8.8</P>
</TD><TD valign=top style='width:12.1%;border-left:1.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'> &nbsp;3,316</P>
</TD><TD valign=top style='width:7.64%;border-right:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'> &nbsp;8.6</P>
</TD><TD valign=top style='width:12.1%;border-left:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'> &nbsp;3,316</P>
</TD><TD valign=top style=width:7.64%><P align=center style='font:10pt Times New Roman;margin:0'> &nbsp;9.2</P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:19.96%><P style='font:10pt Times New Roman;margin:0'>Other&#8211; UK:</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:12.48%><P align=center style='font:10pt Times New Roman;margin:0'> &nbsp;&nbsp;132</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:8.32%;border-right:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:12.1%;border-left:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'> &nbsp;&nbsp;158</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:7.64%;border-right:1.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:12.1%;border-left:1.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;428</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:7.64%;border-right:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:12.1%;border-left:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;470</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:7.64%><P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:19.96%><P style='font:10pt Times New Roman;margin:0'>Other&#8211; US:</P>
</TD><TD valign=top style=width:12.48%><P align=center style='font:10pt Times New Roman;margin:0'> &nbsp;&nbsp;710</P>
</TD><TD valign=top style='width:8.32%;border-right:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:12.1%;border-left:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'> &nbsp;&nbsp;550</P>
</TD><TD valign=top style='width:7.64%;border-right:1.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:12.1%;border-left:1.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>2,018</P>
</TD><TD valign=top style='width:7.64%;border-right:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:12.1%;border-left:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>1,663</P>
</TD><TD valign=top style=width:7.64%><P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:19.96%><P style='font:10pt Times New Roman;margin:0'>IRE:</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:12.48%><P align=center style='font:10pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;73</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:8.32%;border-right:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:12.1%;border-left:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;74</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:7.64%;border-right:1.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:12.1%;border-left:1.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;224</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:7.64%;border-right:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:12.1%;border-left:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;235</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:7.64%><P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:19.96%><P style='font:10pt Times New Roman;margin:0'>AUS:</P>
</TD><TD valign=top style=width:12.48%><P align=center style='font:10pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;39</P>
</TD><TD valign=top style='width:8.32%;border-right:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:12.1%;border-left:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;48</P>
</TD><TD valign=top style='width:7.64%;border-right:1.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:12.1%;border-left:1.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;124</P>
</TD><TD valign=top style='width:7.64%;border-right:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:12.1%;border-left:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;136</P>
</TD><TD valign=top style=width:7.64%><P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:19.96%><P style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>CAN:</FONT></P>
</TD><TD valign=top style=background-color:#CCEEFF;width:12.48%><P align=center style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp;&nbsp;&nbsp;34</FONT></P>
</TD><TD valign=top style='background-color:#CCEEFF;width:8.32%;border-right:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp;</FONT></P>
</TD><TD valign=top style='background-color:#CCEEFF;width:12.1%;border-left:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp;&nbsp;&nbsp;41</FONT></P>
</TD><TD valign=top style='background-color:#CCEEFF;width:7.64%;border-right:1.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:12.1%;border-left:1.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp;&nbsp;106</FONT></P>
</TD><TD valign=top style='background-color:#CCEEFF;width:7.64%;border-right:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:12.1%;border-left:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp;&nbsp;124</FONT></P>
</TD><TD valign=top style=background-color:#CCEEFF;width:7.64%><P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:19.96%><P style='font:10pt Times New Roman;margin:0'>Total G&amp;A:</P>
</TD><TD valign=top style=width:12.48%><P align=center style='font:10pt Times New Roman;margin:0'>2,560</P>
</TD><TD valign=top style='width:8.32%;border-right:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>19.8</P>
</TD><TD valign=top style='width:12.1%;border-left:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>2,524</P>
</TD><TD valign=top style='width:7.64%;border-right:1.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>20.1</P>
</TD><TD valign=top style='width:12.1%;border-left:1.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>7,713</P>
</TD><TD valign=top style='width:7.64%;border-right:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>19.9</P>
</TD><TD valign=top style='width:12.1%;border-left:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>7,598</P>
</TD><TD valign=top style=width:7.64%><P align=center style='font:10pt Times New Roman;margin:0'>21.0</P>
</TD></TR>
</TABLE>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>Over 60% of UTMD&#8217;s consolidated G&amp;A expenses in all periods above were from the non-cash expense of amortizing IIA related to the Filshie Clip System. In other words, IIA amortization G&amp;A expense declined to 12.1% of sales in 3Q 2022 from 13.2% of sales in 3Q 2021; and declined to 12.5% of sales in 9M 2022 from 13.8% of sales in 9M 2021. &nbsp;This essentially explains how UTMD was able to maintain its operating income margin the same in 9M 2022 as in 9M 2021 when its GPM was lower as a result of inflationary cost pressures together with higher litigation expenses. Fixed USD IIA amortization expenses are diluted as a percentage of sales as sales increase. &nbsp;The UK IIA amortization expenses were further diminished as a percentage of USD sales as a result of the lower USD/GBP FX rate.</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>OUS G&amp;A expenses in USD terms were $745 in 3Q 2022 compared to $869 in 3Q 2021. OUS G&amp;A expenses were $2,379 in 9M 2022 compared to $2,619 in 9M 2021. The constant currency table below shows how the stronger USD diminished OUS G&amp;A expenses for 3Q by $120 and 9M 2022 by $243:</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE style=border-collapse:collapse;width:100%><TR><TD valign=bottom style=width:19.96%><P style='font:10pt Times New Roman;margin:0'>G&amp;A Exp <BR><FONT style='border-bottom:1px solid #000000'>Category</FONT></P>
</TD><TD valign=bottom style=width:12.48%><P align=center style='font:10pt Times New Roman;margin:0'>3Q 2022 <BR><FONT style='border-bottom:1px solid #000000'>const FX</FONT></P>
</TD><TD valign=bottom style=width:8.32%><P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style=width:12.1%><P align=center style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>3Q 2021</FONT></P>
</TD><TD valign=bottom style=width:7.64%><P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style=width:12.1%><P align=center style='font:10pt Times New Roman;margin:0'>9M 2022 <FONT style='border-bottom:1px solid #000000'>const FX</FONT></P>
</TD><TD valign=bottom style=width:7.64%><P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style=width:12.1%><P align=center style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>9M 2021</FONT></P>
</TD><TD valign=bottom style=width:7.64%><P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:19.96%><P style='font:10pt Times New Roman;margin:0'>IIA Amort- UK:</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:12.48%><P align=center style='font:10pt Times New Roman;margin:0'>$ 548</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:8.32%><P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:12.1%><P align=center style='font:10pt Times New Roman;margin:0'>$ 548</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:7.64%><P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:12.1%><P align=center style='font:10pt Times New Roman;margin:0'>$1,653</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:7.64%><P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:12.1%><P align=center style='font:10pt Times New Roman;margin:0'>$1,654</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:7.64%><P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:19.96%><P style='font:10pt Times New Roman;margin:0'>Other&#8211; UK:</P>
</TD><TD valign=top style=width:12.48%><P align=center style='font:10pt Times New Roman;margin:0'> &nbsp;&nbsp;155</P>
</TD><TD valign=top style=width:8.32%><P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:12.1%><P align=center style='font:10pt Times New Roman;margin:0'> &nbsp;&nbsp;158</P>
</TD><TD valign=top style=width:7.64%><P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:12.1%><P align=center style='font:10pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;475</P>
</TD><TD valign=top style=width:7.64%><P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:12.1%><P align=center style='font:10pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;470</P>
</TD><TD valign=top style=width:7.64%><P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:19.96%><P style='font:10pt Times New Roman;margin:0'>IRE:</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:12.48%><P align=center style='font:10pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;85</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:8.32%><P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:12.1%><P align=center style='font:10pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;74</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:7.64%><P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:12.1%><P align=center style='font:10pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;254</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:7.64%><P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:12.1%><P align=center style='font:10pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;235</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:7.64%><P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:19.96%><P style='font:10pt Times New Roman;margin:0'>AUS:</P>
</TD><TD valign=top style=width:12.48%><P align=center style='font:10pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;42</P>
</TD><TD valign=top style=width:8.32%><P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:12.1%><P align=center style='font:10pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;48</P>
</TD><TD valign=top style=width:7.64%><P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:12.1%><P align=center style='font:10pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;132</P>
</TD><TD valign=top style=width:7.64%><P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:12.1%><P align=center style='font:10pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;136</P>
</TD><TD valign=top style=width:7.64%><P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:19.96%><P style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>CAN:</FONT></P>
</TD><TD valign=top style=background-color:#CCEEFF;width:12.48%><P align=center style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp;&nbsp;&nbsp;35</FONT></P>
</TD><TD valign=top style=background-color:#CCEEFF;width:8.32%><P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:12.1%><P align=center style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp;&nbsp;41</FONT></P>
</TD><TD valign=top style=background-color:#CCEEFF;width:7.64%><P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:12.1%><P align=center style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp;&nbsp;&nbsp;108</FONT></P>
</TD><TD valign=top style=background-color:#CCEEFF;width:7.64%><P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:12.1%><P align=center style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp;&nbsp;&nbsp;124</FONT></P>
</TD><TD valign=top style=background-color:#CCEEFF;width:7.64%><P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:19.96%><P style='font:10pt Times New Roman;margin:0'>Total OUS G&amp;A:</P>
</TD><TD valign=top style=width:12.48%><P align=center style='font:10pt Times New Roman;margin:0'> &nbsp;&nbsp;865</P>
</TD><TD valign=top style=width:8.32%><P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:12.1%><P align=center style='font:10pt Times New Roman;margin:0'> &nbsp;869</P>
</TD><TD valign=top style=width:7.64%><P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:12.1%><P align=center style='font:10pt Times New Roman;margin:0'> &nbsp;2,622</P>
</TD><TD valign=top style=width:7.64%><P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:12.1%><P align=center style='font:10pt Times New Roman;margin:0'> &nbsp;2,619</P>
</TD><TD valign=top style=width:7.64%><P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
</TABLE>
<HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Income Before Tax (EBT)</FONT> </P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>EBT results from subtracting net non-operating expense (NOE) or adding net non-operating income (NOI) from or to, as applicable, OI. &nbsp;Consolidated 3Q 2022 EBT was $5,339 (41.2% of sales) compared to $5,157 (41.0% of sales) in 3Q 2021. Consolidated 9M 2022 EBT was $15,068 (38.9% of sales) compared to $13,880 (38.4% of sales) in 9M 2021. As UTMD&#8217;s Operating Income ratio was the same in both 9M periods, the improvement in 9M EBT as a percentage of sales was due to higher net NOI. &nbsp;&nbsp;&nbsp;&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>NOE/NOI includes the combination of 1) expenses from loan interest and bank fees; 2) expenses or income from losses or gains from remeasuring the value of EUR cash bank balances in the UK, and GBP cash balances in Ireland, in USD terms; and 3) income from rent of underutilized property, investment income and royalties received from licensing the Company&#8217;s technology. Negative NOE is NOI. &nbsp;Net NOI in 3Q 2022 was $198 compared to $59 NOI in 3Q 2021. Net NOI in 9M 2022 was $348 compared to $130 NOI in 9M 2021. &nbsp;UTMD realized a $7 remeasured currency balance loss in 9M 2022 compared to a $13 loss in 9M 2021. With higher cash balances and interest rates in 2022 compared to 2021, UTMD received $179 more in interest income. NOI generated in Ireland from renting unused warehouse space to a third party yielded a further increase in 9M 2022 NOI compared to 9M 2021. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>EBITDA is a non-US GAAP metric that measures profitability performance without factoring in effects of financing, accounting decisions regarding non-cash expenses, capital expenditures or tax environments. Excluding the noncash effects of depreciation, amortization of intangible assets and stock option expense, 3Q 2022 consolidated EBT excluding the remeasured bank balance currency gain or loss and interest expense (&#8220;adjusted consolidated EBITDA&#8221;) was $7,111 compared to $7,024 in 3Q 2021. &nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>Adjusted consolidated EBITDA was $20,487 in 9M 2022 compared to $19,495 in 9M 2021, a 5.1% increase. Adjusted consolidated EBITDA for the previous four calendar quarters (TTM) was $27,522 as of September 30, 2022. &nbsp;Based on 9M 2022 actual operating results, management expects adjusted consolidated EBITDA of about $28 million for the full year 2022, consistent with previous projections. </P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>UTMD&#8217;s adjusted consolidated EBITDA as a percentage of sales was 54.9% in 3Q 2022 compared to 55.9% in 3Q 2021, reflecting the lower GPM. &nbsp;Similarly, UTMD&#8217;s adjusted consolidated EBITDA as a percentage of sales was 52.9% in 9M 2022 compared to 53.9% in 9M 2021. </P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>Management believes that this operating performance metric provides meaningful supplemental information to both management and investors and confirms UTMD&#8217;s ongoing excellent financial operating performance during a difficult economic period of time. </P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>UTMD&#8217;s non-US GAAP adjusted consolidated EBITDA is the sum of the elements in the following table, each element of which is a US GAAP number:</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE style=border-collapse:collapse;width:100%><TR><TD valign=top style=width:47.9%><P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:11.48%><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>3Q 2022</FONT></P>
</TD><TD valign=top style='width:13.54%;border-right:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>3Q 2021</FONT></P>
</TD><TD valign=top style='width:13.54%;border-left:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>9M 2022</FONT></P>
</TD><TD valign=top style=width:13.54%><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>9M 2021</FONT></P>
</TD></TR>
<TR><TD valign=top style=width:47.9%><P style='font:10pt Times New Roman;margin:0'>EBT</P>
</TD><TD valign=top style=width:11.48%><P align=right style='font:10pt Times New Roman;margin:0'>$5,339</P>
</TD><TD valign=top style='width:13.54%;border-right:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>$5,157</P>
</TD><TD valign=top style='width:13.54%;border-left:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>$15,068</P>
</TD><TD valign=top style=width:13.54%><P align=right style='font:10pt Times New Roman;margin:0'>$13,880</P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:47.9%><P style='font:10pt Times New Roman;margin:0'>Depreciation Expense</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:11.48%><P align=right style='font:10pt Times New Roman;margin:0'>152</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:13.54%;border-right:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>157</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:13.54%;border-left:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>454</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:13.54%><P align=right style='font:10pt Times New Roman;margin:0'>483</P>
</TD></TR>
<TR><TD valign=top style=width:47.9%><P style='font:10pt Times New Roman;margin:0'>Femcare IIA Amqortization Expense</P>
</TD><TD valign=top style=width:11.48%><P align=right style='font:10pt Times New Roman;margin:0'>467</P>
</TD><TD valign=top style='width:13.54%;border-right:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>548</P>
</TD><TD valign=top style='width:13.54%;border-left:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>1,497</P>
</TD><TD valign=top style=width:13.54%><P align=right style='font:10pt Times New Roman;margin:0'>1,653</P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:47.9%><P style='font:10pt Times New Roman;margin:0'>CSI IIA Amortization Expenseq</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:11.48%><P align=right style='font:10pt Times New Roman;margin:0'>1,105</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:13.54%;border-right:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>1,105</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:13.54%;border-left:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>3,316</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:13.54%><P align=right style='font:10pt Times New Roman;margin:0'>3,316</P>
</TD></TR>
<TR><TD valign=top style=width:47.9%><P style='font:10pt Times New Roman;margin:0'>Other Non-Cash Amortization Expense</P>
</TD><TD valign=top style=width:11.48%><P align=right style='font:10pt Times New Roman;margin:0'> 8</P>
</TD><TD valign=top style='width:13.54%;border-right:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>9</P>
</TD><TD valign=top style='width:13.54%;border-left:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>24</P>
</TD><TD valign=top style=width:13.54%><P align=right style='font:10pt Times New Roman;margin:0'>27</P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:47.9%><P style='font:10pt Times New Roman;margin:0'>Stock Option Compensation Expense</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:11.48%><P align=right style='font:10pt Times New Roman;margin:0'>38</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:13.54%;border-right:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>41</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:13.54%;border-left:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>121</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:13.54%><P align=right style='font:10pt Times New Roman;margin:0'>123</P>
</TD></TR>
<TR><TD valign=top style=width:47.9%><P style='font:10pt Times New Roman;margin:0'>Interest Expense</P>
</TD><TD valign=top style=width:11.48%><P align=right style='font:10pt Times New Roman;margin:0'>- </P>
</TD><TD valign=top style='width:13.54%;border-right:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>-</P>
</TD><TD valign=top style='width:13.54%;border-left:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>- </P>
</TD><TD valign=top style=width:13.54%><P align=center style='font:10pt Times New Roman;margin:0;margin-left:36pt'>-</P>
</TD></TR>
<TR><TD valign=top style='background-color:#CCEEFF;width:47.9%;border-bottom:0.5pt solid #000000'><P style='font:10pt Times New Roman;margin:0'>Remeasured Foreign Currency Balances</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:11.48%;border-bottom:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>2</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:13.54%;border-bottom:0.5pt solid #000000;border-right:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>7</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:13.54%;border-left:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>7</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:13.54%;border-bottom:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>13</P>
</TD></TR>
<TR><TD valign=top style='width:47.9%;border-top:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>UTMD non-US GAAP EBITDA:</P>
</TD><TD valign=top style='width:11.48%;border-top:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>$7,111</P>
</TD><TD valign=top style='width:13.54%;border-top:0.5pt solid #000000;border-right:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>$7,024</P>
</TD><TD valign=top style='width:13.54%;border-top:0.5pt solid #000000;border-left:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>$20,487</P>
</TD><TD valign=top style='width:13.54%;border-top:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>$19,495</P>
</TD></TR>
</TABLE>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Note</FONT></P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>All UTMD income statement measures from GP through EBT (and including non-US GAAP adjusted consolidated EBITDA above) for both 2022 and 2021 time periods were unaffected by the enacted changes in the UK corporate income tax rate.</P>
<HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Net Income (NI)</FONT> </P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>NI in 3Q 2022 of $4,280 (33.0% of sales) was 1.8% higher than NI of $4,206 (33.5% of sales) in 3Q 2021. NI in 9M 2022 of $11,918 (30.8% of sales) was 11.8% higher than the US GAAP NI of $10,656 (29.5% of sales) in 9M 2021. </P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>NI per US GAAP in 9M 2021 was reduced by an additional tax provision expense required to be recorded in the quarter in which a tax change is enacted, as a result of an adjustment to UTMD&#8217;s deferred tax liability (DTL). &nbsp;The DTL results from the tax effect of not being able to deduct remaining future amortization expense of Femcare IIA. &nbsp;In 2Q 2021, because the UK reset its corporate tax rate from 19% to 25% beginning with 2Q 2023, it caused UTMD to have to book an additional $390 in its 2Q 2021 income tax provision that represents the additional tax which will be paid in the UK over the then remaining five year life of the 2011 Femcare acquisition IIA. Excluding the $390 DTL increase in 2Q 2021, which reduced 9M 2021 NI by that same amount, 9M 2022 NI was 7.9% higher than 9M 2021 non-US GAAP NI of $11,047 (30.6% of sales), which management believes is more indicative of operating results. </P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>The average consolidated income tax provisions (as a % of the same period EBT) per US GAAP in 3Q 2022 and 3Q 2021 were 19.8% and 18.4% respectively, and were 20.9% and 23.2% in 9M 2022 and 9M 2021 respectively. Please recall that the 9M 2021 income tax provision was inflated by $390 for the 2Q 2021 DTL adjustment. The non-US GAAP income tax provision rate was 20.4% for 9M 2021. </P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>The consolidated income tax provision rate varies as the mix in taxable income among U.S. and foreign subsidiaries with differing income tax rates differs from period to period. UTMD has consistently paid millions of dollars in income taxes annually. The basic corporate income tax rates in each of the sovereignties were the same as in the prior year. </P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Earnings per share (EPS)</FONT>. &nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>Diluted EPS in 3Q 2022 were $1.178 compared to $1.150 in 3Q 2021, a 2.4% increase. Diluted EPS in 9M 2022 were $3.265 compared to US GAAP diluted EPS of $2.915 in 9M 2021, a 12.0% increase. &nbsp;Backing out the 2021 &#8220;one-time&#8221; income tax provision increase due to the DTL adjustment, non-US GAAP diluted EPS in 9M 2021 were $3.021. The 8.1% increase in 9M 2022 diluted EPS compared to non-US GAAP diluted EPS in 9M 2021 was consistent with the increase in EBT, given a slightly higher average consolidated income tax rate. Diluted shares were 3,634,235 in 3Q 2022 compared to 3,657,733 in 3Q 2021. The lower diluted shares in 3Q 2022 were the result of UTMD shares repurchased in 2Q 2022, offset slightly by employee options exercised. </P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>The number of shares used for calculating 3Q 2022 EPS was higher than September 30, 2022 actual outstanding shares because of a time-weighted calculation of average outstanding shares plus dilution from unexercised employee and director options. Outstanding shares at the end of 3Q 2022 were 3,625,195 compared to 3,654,737 at the end of calendar year 2021. The difference was due to 30,105 shares repurchased in 2Q 2022 less 563 shares in employee option exercises during 9M 2022. For comparison, actual outstanding shares were 3,648,984 at the end of 3Q 2021. The total number of outstanding unexercised employee and outside director options at September 30, 2022 was 49,895 at an average exercise price of $69.00, including shares awarded but not yet vested. &nbsp;This compares to 59,869 unexercised option shares at the end of 3Q 2021 at an average exercise price of $68.74/ share, including shares awarded but not vested. </P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>The number of shares added as a dilution factor for 3Q 2022 was 9,220 compared to 10,933 in 3Q 2021. The number of shares added as a dilution factor for 9M 2022 was 9,424 compared to 10,685 in 9M 2021. No options were awarded in 2021 or through 9M 2022. &nbsp;UTMD paid $1,051 ($0.290/share) in dividends to stockholders in 3Q 2022 compared to $1,039 ($0.285/ share) paid in 3Q 2021. Dividends paid to stockholders during 3Q 2022 were 25% of &nbsp;3Q 2022 NI. UTMD paid $2,111 ($0.290/share) in dividends to stockholders in 9M 2022 compared to $3,116 ($0.285/ share) paid in 9M 2021. The difference was due to an earlier payment of a special dividend at the end of 2021 instead of in 1Q 2022. No UTMD shares were purchased in the open market in 2021. In 2Q 2022, the Company purchased 30,105 UTMD shares at an average cost of $82.88/ share. The Company retains the strong desire and financial ability for repurchasing its shares at a price it believes is attractive for remaining stockholders. </P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>UTMD&#8217;s closing share price at the end of 3Q 2022 was $85.31, down from the closing price of $85.90 three months earlier at the end of 2Q 2022, and the closing price of $100.00 nine months earlier at the end of 2021. &nbsp;&nbsp;&nbsp;</P>
<HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<P style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Balance Sheet</FONT>.</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>At September 30, 2022, UTMD&#8217;s cash and investments increased $8,537 to $69,511 from $60,974 at the end of 2021, despite using cash during 9M 2022 to pay $2,111 in dividends to stockholders, $2,495 to repurchase UTMD shares, $771 to purchase new manufacturing equipment, plus changes in working capital including $1,713 to grow inventories to hedge against supply chain disruption and $903 higher accounts receivable as a result of higher sales activity. The net increase in cash was provided by UTMD&#8217;s excellent operating 9M EBITDA of $20,487. At September 30, 2022, Net Intangible Assets decreased to 20.2% of total consolidated assets from 27.2% on December 31, 2021. &nbsp;In addition to $4,837 in amortization, a stronger USD reduced the USD value of Femcare&#8217;s GBP IIA. &nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>Financial ratios as of September 30, 2022 which may be of interest to stockholders follow:</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:18pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-18pt'>1)</KBD>Current Ratio = 13.4&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;text-indent:-18pt;margin-left:18pt'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:18pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-18pt'>2)</KBD>Days in Trade Receivables (based on 3Q 2022 sales activity) = 41.8&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;text-indent:-18pt;margin-left:18pt'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:18pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-18pt'>3)</KBD>Average Inventory Turns (based on 3Q 2022 average inventory and CGS) = 2.4&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;text-indent:-18pt;margin-left:18pt'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:18pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-18pt'>4)</KBD>2022 YTD ROE (before dividends) = 15%&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;text-indent:-18pt;margin-left:18pt'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>Investors are cautioned that this press release contains forward looking statements and that actual events may differ from those projected. &nbsp;Risk factors that could cause results to differ materially from those projected include global economic conditions, market acceptance of products, regulatory approvals of products, regulatory intervention in current operations, government intervention in healthcare in general, tax reforms, the Company&#8217;s ability to efficiently manufacture, market and sell products, cybersecurity and foreign currency exchange rates, among other factors that have been and will be outlined in UTMD&#8217;s public disclosure filings with the SEC. &nbsp;UTMD&#8217;s 3Q 2022 SEC Form 10-Q will be filed on or before November 15, 2022, and can be accessed on <FONT style='color:#0000FF;border-bottom:1px solid #0000FF'><B><I>www.utahmed.com</I></B></FONT>.</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>Utah Medical Products, Inc., with particular interest in health care for women and their babies, develops, manufactures and markets a broad range of disposable and reusable specialty medical devices recognized by clinicians in over one hundred countries around the world as the standard for obtaining optimal long term outcomes for their patients. &nbsp;For more information about Utah Medical Products, Inc., visit UTMD&#8217;s website at<B><I> </I></B><FONT style='color:#0000FF;border-bottom:1px solid #0000FF'><B><I>www.utahmed.com</I></B></FONT>.</P>
<HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>Utah Medical Products, Inc.</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>INCOME STATEMENT, Third Quarter (three months ended September 30)</P>
<P style='font:10pt Times New Roman;margin:0'>(in thousands except earnings per share):</P>
<TABLE style=border-collapse:collapse;width:100%><TR><TD valign=top style=width:38.9%><P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:18.7%><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>3Q 2022</FONT></P>
</TD><TD valign=top style=width:19.5%><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>3Q 2021</FONT></P>
</TD><TD valign=top style=width:22.9%><P align=center style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Percent Change</FONT></P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:38.9%><P style='font:10pt Times New Roman;margin:0'>Net Sales</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:18.7%><P align=right style='font:10pt Times New Roman;margin:0'>$ 12,955</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:19.5%><P align=right style='font:10pt Times New Roman;margin:0'>$12,572</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:22.9%><P align=center style='font:10pt Times New Roman;margin:0'>3.0%</P>
</TD></TR>
<TR><TD valign=top style=width:38.9%><P style='font:10pt Times New Roman;margin:0'>Gross Profit</P>
</TD><TD valign=top style=width:18.7%><P align=right style='font:10pt Times New Roman;margin:0'>8,186</P>
</TD><TD valign=top style=width:19.5%><P align=right style='font:10pt Times New Roman;margin:0'>8,073</P>
</TD><TD valign=top style=width:22.9%><P align=center style='font:10pt Times New Roman;margin:0'>1.4%</P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:38.9%><P style='font:10pt Times New Roman;margin:0'>Operating Income</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:18.7%><P align=right style='font:10pt Times New Roman;margin:0'>5,141</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:19.5%><P align=right style='font:10pt Times New Roman;margin:0'>5,098</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:22.9%><P align=center style='font:10pt Times New Roman;margin:0'>0.8%</P>
</TD></TR>
<TR><TD valign=top style='width:38.9%;border-bottom:0.5pt solid #000000'><P style='font:10pt Times New Roman;margin:0'>Income Before Tax</P>
</TD><TD valign=top style='width:18.7%;border-bottom:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>5,339</P>
</TD><TD valign=top style='width:19.5%;border-bottom:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>5,157</P>
</TD><TD valign=top style='width:22.9%;border-bottom:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>3.5%</P>
</TD></TR>
<TR><TD valign=top style='background-color:#CCEEFF;width:38.9%;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P style='font:10pt Times New Roman;margin:0'>Net Income (US GAAP)</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:18.7%;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>4,280</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:19.5%;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>4,206</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:22.9%;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>1.8%</P>
</TD></TR>
<TR><TD valign=top style='width:38.9%;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P style='font:10pt Times New Roman;margin:0'>Earnings Per Share (US GAAP)</P>
</TD><TD valign=top style='width:18.7%;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>$1.178</P>
</TD><TD valign=top style='width:19.5%;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>$ 1.150</P>
</TD><TD valign=top style='width:22.9%;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>2.4%</P>
</TD></TR>
<TR><TD valign=top style='background-color:#CCEEFF;width:38.9%;border-top:0.5pt solid #000000'><P style='font:10pt Times New Roman;margin:0'>Shares Outstanding (diluted)</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:18.7%;border-top:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>3,634</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:19.5%;border-top:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>3,658</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:22.9%;border-top:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
</TABLE>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>INCOME STATEMENT, First Nine Months (nine months ended September 30)</P>
<P style='font:10pt Times New Roman;margin:0'>(in thousands except earnings per share): </P>
<TABLE style=border-collapse:collapse;width:100%><TR><TD valign=top style=width:37.76%><P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:20.58%><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>9M 2022</FONT></P>
</TD><TD valign=top style=width:20.2%><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>9M 2021</FONT></P>
</TD><TD valign=top style=width:21.46%><P align=center style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Percent Change</FONT></P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:37.76%><P style='font:10pt Times New Roman;margin:0'>Net Sales</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:20.58%><P align=right style='font:10pt Times New Roman;margin:0'>$ 38,707</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:20.2%><P align=right style='font:10pt Times New Roman;margin:0'>$ 36,140</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:21.46%><P align=center style='font:10pt Times New Roman;margin:0'> 7.1%</P>
</TD></TR>
<TR><TD valign=top style=width:37.76%><P style='font:10pt Times New Roman;margin:0'>Gross Profit</P>
</TD><TD valign=top style=width:20.58%><P align=right style='font:10pt Times New Roman;margin:0'>23,869</P>
</TD><TD valign=top style=width:20.2%><P align=right style='font:10pt Times New Roman;margin:0'>22,804</P>
</TD><TD valign=top style=width:21.46%><P align=center style='font:10pt Times New Roman;margin:0'> 4.7%</P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:37.76%><P style='font:10pt Times New Roman;margin:0'>Operating Income</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:20.58%><P align=right style='font:10pt Times New Roman;margin:0'>14,720</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:20.2%><P align=right style='font:10pt Times New Roman;margin:0'>13,750</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:21.46%><P align=center style='font:10pt Times New Roman;margin:0'> 7.1%</P>
</TD></TR>
<TR><TD valign=top style='width:37.76%;border-bottom:0.5pt solid #000000'><P style='font:10pt Times New Roman;margin:0'>Income Before Tax</P>
</TD><TD valign=top style='width:20.58%;border-bottom:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>15,068</P>
</TD><TD valign=top style='width:20.2%;border-bottom:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>13,880</P>
</TD><TD valign=top style='width:21.46%;border-bottom:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'> 8.6%</P>
</TD></TR>
<TR><TD valign=top style='background-color:#CCEEFF;width:37.76%;border-top:0.5pt solid #000000'><P style='font:10pt Times New Roman;margin:0'><I>Net Income before DTL adjust</I></P>
</TD><TD valign=top style='background-color:#CCEEFF;width:20.58%;border-top:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'><I>11,918</I></P>
</TD><TD valign=top style='background-color:#CCEEFF;width:20.2%;border-top:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'><I>11,047</I></P>
</TD><TD valign=top style='background-color:#CCEEFF;width:21.46%;border-top:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'><I>7.9%</I></P>
</TD></TR>
<TR><TD valign=top style='width:37.76%;border-bottom:0.5pt solid #000000'><P style='font:10pt Times New Roman;margin:0'>Net Income (US GAAP)</P>
</TD><TD valign=top style='width:20.58%;border-bottom:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>11,918</P>
</TD><TD valign=top style='width:20.2%;border-bottom:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>10,656</P>
</TD><TD valign=top style='width:21.46%;border-bottom:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>11.8%</P>
</TD></TR>
<TR><TD valign=top style='background-color:#CCEEFF;width:37.76%;border-top:0.5pt solid #000000'><P style='font:10pt Times New Roman;margin:0'><I>EPS before DTL adjustment</I></P>
</TD><TD valign=top style='background-color:#CCEEFF;width:20.58%;border-top:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'><I>$ 3.265</I></P>
</TD><TD valign=top style='background-color:#CCEEFF;width:20.2%;border-top:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'><I>$ 3.021</I></P>
</TD><TD valign=top style='background-color:#CCEEFF;width:21.46%;border-top:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'><I>8.1%</I></P>
</TD></TR>
<TR><TD valign=top style='width:37.76%;border-bottom:0.5pt solid #000000'><P style='font:10pt Times New Roman;margin:0'>EPS (US GAAP)</P>
</TD><TD valign=top style='width:20.58%;border-bottom:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>$ 3.265</P>
</TD><TD valign=top style='width:20.2%;border-bottom:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>$ 2.915</P>
</TD><TD valign=top style='width:21.46%;border-bottom:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>12.0%</P>
</TD></TR>
<TR><TD valign=top style='background-color:#CCEEFF;width:37.76%;border-top:0.5pt solid #000000'><P style='font:10pt Times New Roman;margin:0'>Shares Outstanding (diluted)</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:20.58%;border-top:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>3,650</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:20.2%;border-top:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>3,656</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:21.46%;border-top:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
</TABLE>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>BALANCE SHEET</P>
<TABLE style=border-collapse:collapse;width:100%><TR><TD valign=top style=width:41.04%><P style='font:10pt Times New Roman;margin:0'>(in thousands)</P>
</TD><TD valign=top style=width:14.32%><P align=right style='font:10pt Times New Roman;margin:0'>(unaudited)</P>
<P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>SEP 30, 2022</FONT></P>
</TD><TD valign=top style=width:15.12%><P align=right style='font:10pt Times New Roman;margin:0'>(unaudited)</P>
<P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>JUN 30, 2022</FONT></P>
</TD><TD valign=top style=width:14.58%><P align=right style='font:10pt Times New Roman;margin:0'>(audited)</P>
<P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>DEC 31, 2021</FONT></P>
</TD><TD valign=top style=width:14.92%><P align=right style='font:10pt Times New Roman;margin:0'>(unaudited)</P>
<P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>SEP 30, 2021</FONT></P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:41.04%><P style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Assets</FONT></P>
</TD><TD valign=top style=background-color:#CCEEFF;width:14.32%><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:15.12%><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:14.58%><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:14.92%><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:41.04%><P style='font:10pt Times New Roman;margin:0;margin-left:9pt'>Cash &amp; Investments</P>
</TD><TD valign=top style=width:14.32%><P align=right style='font:10pt Times New Roman;margin:0'>$69,511</P>
</TD><TD valign=top style=width:15.12%><P align=right style='font:10pt Times New Roman;margin:0'>$66,224</P>
</TD><TD valign=top style=width:14.58%><P align=right style='font:10pt Times New Roman;margin:0'>$60,974</P>
</TD><TD valign=top style=width:14.92%><P align=right style='font:10pt Times New Roman;margin:0'>$64,321</P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:41.04%><P style='font:10pt Times New Roman;margin:0;margin-left:9pt'>Accounts &amp; Other Receivables, Net</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:14.32%><P align=right style='font:10pt Times New Roman;margin:0'>6,034</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:15.12%><P align=right style='font:10pt Times New Roman;margin:0'>4,938</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:14.58%><P align=right style='font:10pt Times New Roman;margin:0'>5,132</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:14.92%><P align=right style='font:10pt Times New Roman;margin:0'>4,853</P>
</TD></TR>
<TR><TD valign=top style=width:41.04%><P style='font:10pt Times New Roman;margin:0;margin-left:9pt'>Inventories</P>
</TD><TD valign=top style=width:14.32%><P align=right style='font:10pt Times New Roman;margin:0'>8,310</P>
</TD><TD valign=top style=width:15.12%><P align=right style='font:10pt Times New Roman;margin:0'>7,338</P>
</TD><TD valign=top style=width:14.58%><P align=right style='font:10pt Times New Roman;margin:0'>6,596</P>
</TD><TD valign=top style=width:14.92%><P align=right style='font:10pt Times New Roman;margin:0'>6,299</P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:41.04%><P style='font:10pt Times New Roman;margin:0;margin-left:9pt'>Other Current Assets</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:14.32%><P align=right style='font:10pt Times New Roman;margin:0'>387</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:15.12%><P align=right style='font:10pt Times New Roman;margin:0'>453</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:14.58%><P align=right style='font:10pt Times New Roman;margin:0'>456</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:14.92%><P align=right style='font:10pt Times New Roman;margin:0'>373</P>
</TD></TR>
<TR><TD valign=top style=width:41.04%><P style='font:10pt Times New Roman;margin:0;margin-left:18pt'>Total Current Assets</P>
</TD><TD valign=top style=width:14.32%><P align=right style='font:10pt Times New Roman;margin:0'>84,242</P>
</TD><TD valign=top style=width:15.12%><P align=right style='font:10pt Times New Roman;margin:0'>78,953</P>
</TD><TD valign=top style=width:14.58%><P align=right style='font:10pt Times New Roman;margin:0'>73,158</P>
</TD><TD valign=top style=width:14.92%><P align=right style='font:10pt Times New Roman;margin:0'>75,846</P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:41.04%><P style='font:10pt Times New Roman;margin:0'>Property &amp; Equipment, Net</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:14.32%><P align=right style='font:10pt Times New Roman;margin:0'>10,257</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:15.12%><P align=right style='font:10pt Times New Roman;margin:0'>10,591</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:14.58%><P align=right style='font:10pt Times New Roman;margin:0'>11,066</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:14.92%><P align=right style='font:10pt Times New Roman;margin:0'>10,932</P>
</TD></TR>
<TR><TD valign=top style='width:41.04%;border-bottom:0.75pt solid #000000'><P style='font:10pt Times New Roman;margin:0'>Intangible Assets, Net</P>
</TD><TD valign=top style='width:14.32%;border-bottom:0.75pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>23,914</P>
</TD><TD valign=top style='width:15.12%;border-bottom:0.75pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>26,605</P>
</TD><TD valign=top style='width:14.58%;border-bottom:0.75pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>31,412</P>
</TD><TD valign=top style='width:14.92%;border-bottom:0.75pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>32,974</P>
</TD></TR>
<TR><TD valign=top style='background-color:#CCEEFF;width:41.04%;border-top:0.75pt solid #000000'><P style='font:10pt Times New Roman;margin:0;margin-left:27pt'>Total Assets</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:14.32%;border-top:0.75pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>$118,413</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:15.12%;border-top:0.75pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>$116,149</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:14.58%;border-top:0.75pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>$115,636</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:14.92%;border-top:0.75pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>$119,752</P>
</TD></TR>
<TR><TD valign=top style=width:41.04%><P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:14.32%><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:15.12%><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:14.58%><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:14.92%><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:41.04%><P style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Liabilities &amp; Stockholders&#8217; Equity</FONT></P>
</TD><TD valign=top style=background-color:#CCEEFF;width:14.32%><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:15.12%><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:14.58%><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:14.92%><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style='width:41.04%;border-bottom:0.75pt solid #000000'><P style='font:10pt Times New Roman;margin:0'>Accounts Payable</P>
</TD><TD valign=top style='width:14.32%;border-bottom:0.75pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>$ &nbsp;1,289</P>
</TD><TD valign=top style='width:15.12%;border-bottom:0.75pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>$ &nbsp;818</P>
</TD><TD valign=top style='width:14.58%;border-bottom:0.75pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>$ &nbsp;&nbsp;761</P>
</TD><TD valign=top style='width:14.92%;border-bottom:0.75pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>$ &nbsp;&nbsp;1,026</P>
</TD></TR>
<TR><TD valign=top style='background-color:#CCEEFF;width:41.04%;border-top:0.75pt solid #000000'><P style='font:10pt Times New Roman;margin:0'>REPAT Tax Payable</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:14.32%;border-top:0.75pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>220</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:15.12%;border-top:0.75pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>220</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:14.58%;border-top:0.75pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>220</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:14.92%;border-top:0.75pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0;margin-left:18pt'>237 </P>
</TD></TR>
<TR><TD valign=top style='width:41.04%;border-bottom:0.75pt solid #000000'><P style='font:10pt Times New Roman;margin:0'>Other Accrued Liabilities</P>
</TD><TD valign=top style='width:14.32%;border-bottom:0.75pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>4,760</P>
</TD><TD valign=top style='width:15.12%;border-bottom:0.75pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>3,401</P>
</TD><TD valign=top style='width:14.58%;border-bottom:0.75pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>2,765</P>
</TD><TD valign=top style='width:14.92%;border-bottom:0.75pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>3,752</P>
</TD></TR>
<TR><TD valign=top style='background-color:#CCEEFF;width:41.04%;border-top:0.75pt solid #000000'><P style='font:10pt Times New Roman;margin:0;margin-left:9pt'>Total Current Liabilities</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:14.32%;border-top:0.75pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'> &nbsp;$6,269</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:15.12%;border-top:0.75pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'> &nbsp;$4,439</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:14.58%;border-top:0.75pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'> &nbsp;$3,746</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:14.92%;border-top:0.75pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'> &nbsp;$5,015</P>
</TD></TR>
<TR><TD valign=top style=width:41.04%><P style='font:10pt Times New Roman;margin:0'>Deferred Tax Liability &#8211;&nbsp;Intangible Assets</P>
</TD><TD valign=top style=width:14.32%><P align=right style='font:10pt Times New Roman;margin:0'>1,479</P>
</TD><TD valign=top style=width:15.12%><P align=right style='font:10pt Times New Roman;margin:0'>1,707</P>
</TD><TD valign=top style=width:14.58%><P align=right style='font:10pt Times New Roman;margin:0'>2,104</P>
</TD><TD valign=top style=width:14.92%><P align=right style='font:10pt Times New Roman;margin:0'>2,196</P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:41.04%><P style='font:10pt Times New Roman;margin:0'>Long Term Lease Liability</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>Long Term REPAT Tax Payable</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:14.32%><P align=right style='font:10pt Times New Roman;margin:0'>354</P>
<P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=right style='font:10pt Times New Roman;margin:0'>1,675</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:15.12%><P align=right style='font:10pt Times New Roman;margin:0'>368</P>
<P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=right style='font:10pt Times New Roman;margin:0'>1,675</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:14.58%><P align=right style='font:10pt Times New Roman;margin:0'>396</P>
<P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=right style='font:10pt Times New Roman;margin:0'>1,675</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:14.92%><P align=right style='font:10pt Times New Roman;margin:0;margin-left:36pt'>343</P>
<P align=right style='font:10pt Times New Roman;margin:0;margin-left:36pt'>&nbsp;</P>
<P align=right style='font:10pt Times New Roman;margin:0;margin-left:36pt'>1,810</P>
</TD></TR>
<TR><TD valign=top style=width:41.04%><P style='font:10pt Times New Roman;margin:0'>Deferred Revenue and Income Taxes</P>
</TD><TD valign=top style=width:14.32%><P align=right style='font:10pt Times New Roman;margin:0'>450</P>
</TD><TD valign=top style=width:15.12%><P align=right style='font:10pt Times New Roman;margin:0'>489</P>
</TD><TD valign=top style=width:14.58%><P align=right style='font:10pt Times New Roman;margin:0'>577</P>
</TD><TD valign=top style=width:14.92%><P align=right style='font:10pt Times New Roman;margin:0'>408</P>
</TD></TR>
<TR><TD valign=top style='background-color:#CCEEFF;width:41.04%;border-bottom:0.75pt solid #000000'><P style='font:10pt Times New Roman;margin:0'>Stockholders&#8217; Equity</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:14.32%;border-bottom:0.75pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>108,186</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:15.12%;border-bottom:0.75pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>107,471</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:14.58%;border-bottom:0.75pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>107,138</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:14.92%;border-bottom:0.75pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>109,980</P>
</TD></TR>
<TR><TD valign=top style='width:41.04%;border-top:0.75pt solid #000000'><P style='font:10pt Times New Roman;margin:0;margin-left:27pt'>Total Liabilities &amp; Stockholders&#8217; Equity</P>
</TD><TD valign=top style='width:14.32%;border-top:0.75pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>$118,413</P>
</TD><TD valign=top style='width:15.12%;border-top:0.75pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>$116,149</P>
</TD><TD valign=top style='width:14.58%;border-top:0.75pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>$115,636</P>
</TD><TD valign=top style='width:14.92%;border-top:0.75pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>$119,752</P>
</TD></TR>
</TABLE>
<P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>3
<FILENAME>utmd-20221025_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2022 [PPXK5GW761L0VGS139PY]. www.edgarsuite.com -->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase"
		xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
		xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"
		xmlns:fil="http://utahmed.com/20221025"
		xmlns:link="http://www.xbrl.org/2003/linkbase"
		xmlns:xlink="http://www.w3.org/1999/xlink"
		xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
		xmlns:xbrli="http://www.xbrl.org/2003/instance">
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
	<link:roleRef roleURI="http://utahmed.com/20221025/role/idr_DocumentDocumentAndEntityInformation" xlink:type="simple" xlink:href="utmd-20221025.xsd#idr_DocumentDocumentAndEntityInformation"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://utahmed.com/20221025/role/idr_DocumentDocumentAndEntityInformation"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>utmd-20221025_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABELS LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2022 [PPXK5GW761L0VGS139PY]. www.edgarsuite.com -->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase"
		xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
		xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"
		xmlns:fil="http://utahmed.com/20221025"
		xmlns:link="http://www.xbrl.org/2003/linkbase"
		xmlns:xlink="http://www.w3.org/1999/xlink"
		xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
		xmlns:xbrli="http://www.xbrl.org/2003/instance">
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/>
	<link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode' xlink:label='dei_EntityIncorporationStateCountryCode'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityIncorporationStateCountryCode' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Incorporation, State or Country Code</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityIncorporationStateCountryCode' xlink:to='lab_dei_EntityIncorporationStateCountryCode'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode' xlink:label='dei_EntityAddressPostalZipCode'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityAddressPostalZipCode' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Address, Postal Zip Code</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityAddressPostalZipCode' xlink:to='lab_dei_EntityAddressPostalZipCode'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness' xlink:label='dei_EntitySmallBusiness'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntitySmallBusiness' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Small Business</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntitySmallBusiness' xlink:to='lab_dei_EntitySmallBusiness'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications' xlink:label='dei_WrittenCommunications'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_WrittenCommunications' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Written Communications</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_WrittenCommunications' xlink:to='lab_dei_WrittenCommunications'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers' xlink:label='dei_EntityVoluntaryFilers'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityVoluntaryFilers' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Voluntary filer</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityVoluntaryFilers' xlink:to='lab_dei_EntityVoluntaryFilers'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription' xlink:label='dei_AmendmentDescription'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_AmendmentDescription' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Amendment Description</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_AmendmentDescription' xlink:to='lab_dei_AmendmentDescription'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat' xlink:label='dei_EntityPublicFloat'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityPublicFloat' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Public Float</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityPublicFloat' xlink:to='lab_dei_EntityPublicFloat'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName' xlink:label='dei_EntityRegistrantName'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityRegistrantName' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Registrant Name</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityRegistrantName' xlink:to='lab_dei_EntityRegistrantName'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode' xlink:label='dei_CityAreaCode'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_CityAreaCode' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>City Area Code</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_CityAreaCode' xlink:to='lab_dei_CityAreaCode'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate' xlink:label='dei_CurrentFiscalYearEndDate'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_CurrentFiscalYearEndDate' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Fiscal Year End</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_CurrentFiscalYearEndDate' xlink:to='lab_dei_CurrentFiscalYearEndDate'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus' xlink:label='dei_EntityCurrentReportingStatus'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityCurrentReportingStatus' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Current with reporting</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityCurrentReportingStatus' xlink:to='lab_dei_EntityCurrentReportingStatus'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_TextBlockAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Details</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_TextBlockAbstract' xlink:to='lab_us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany' xlink:label='dei_EntityShellCompany'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityShellCompany' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Shell Company</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityShellCompany' xlink:to='lab_dei_EntityShellCompany'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent' xlink:label='dei_EntityInteractiveDataCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityInteractiveDataCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Interactive Data Current</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityInteractiveDataCurrent' xlink:to='lab_dei_EntityInteractiveDataCurrent'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer' xlink:label='dei_PreCommencementTenderOffer'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_PreCommencementTenderOffer' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Pre-commencement Tender Offer</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_PreCommencementTenderOffer' xlink:to='lab_dei_PreCommencementTenderOffer'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer' xlink:label='dei_EntityWellKnownSeasonedIssuer'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityWellKnownSeasonedIssuer' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Well-known Seasoned Issuer</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityWellKnownSeasonedIssuer' xlink:to='lab_dei_EntityWellKnownSeasonedIssuer'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate' xlink:label='dei_DocumentPeriodEndDate'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_DocumentPeriodEndDate' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Period End date</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_DocumentPeriodEndDate' xlink:to='lab_dei_DocumentPeriodEndDate'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer' xlink:label='dei_PreCommencementIssuerTenderOffer'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_PreCommencementIssuerTenderOffer' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Pre-commencement Issuer Tender Offer</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_PreCommencementIssuerTenderOffer' xlink:to='lab_dei_PreCommencementIssuerTenderOffer'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown' xlink:label='dei_EntityAddressCityOrTown'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityAddressCityOrTown' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Address, City or Town</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityAddressCityOrTown' xlink:to='lab_dei_EntityAddressCityOrTown'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber' xlink:label='dei_LocalPhoneNumber'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_LocalPhoneNumber' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Local Phone Number</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_LocalPhoneNumber' xlink:to='lab_dei_LocalPhoneNumber'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber' xlink:label='dei_EntityTaxIdentificationNumber'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityTaxIdentificationNumber' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Tax Identification Number (TIN)</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityTaxIdentificationNumber' xlink:to='lab_dei_EntityTaxIdentificationNumber'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName' xlink:label='dei_SecurityExchangeName'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_SecurityExchangeName' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Trading Exchange</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_SecurityExchangeName' xlink:to='lab_dei_SecurityExchangeName'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType' xlink:label='dei_DocumentType'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_DocumentType' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>SEC Form</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_DocumentType' xlink:to='lab_dei_DocumentType'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod' xlink:label='dei_EntityExTransitionPeriod'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityExTransitionPeriod' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Ex Transition Period</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityExTransitionPeriod' xlink:to='lab_dei_EntityExTransitionPeriod'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory' xlink:label='dei_EntityFilerCategory'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityFilerCategory' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Filer Category</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityFilerCategory' xlink:to='lab_dei_EntityFilerCategory'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding' xlink:label='dei_EntityCommonStockSharesOutstanding'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityCommonStockSharesOutstanding' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Number of common stock shares outstanding</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityCommonStockSharesOutstanding' xlink:to='lab_dei_EntityCommonStockSharesOutstanding'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial' xlink:label='dei_SolicitingMaterial'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_SolicitingMaterial' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Soliciting Material</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_SolicitingMaterial' xlink:to='lab_dei_SolicitingMaterial'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1' xlink:label='dei_EntityAddressAddressLine1'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityAddressAddressLine1' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Address, Address Line One</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityAddressAddressLine1' xlink:to='lab_dei_EntityAddressAddressLine1'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag' xlink:label='dei_AmendmentFlag'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_AmendmentFlag' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Amendment Flag</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_AmendmentFlag' xlink:to='lab_dei_AmendmentFlag'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber' xlink:label='dei_EntityFileNumber'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityFileNumber' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity File Number</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityFileNumber' xlink:to='lab_dei_EntityFileNumber'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany' xlink:label='dei_EntityEmergingGrowthCompany'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityEmergingGrowthCompany' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Emerging Growth Company</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityEmergingGrowthCompany' xlink:to='lab_dei_EntityEmergingGrowthCompany'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol' xlink:label='dei_TradingSymbol'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_TradingSymbol' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Trading Symbol</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_TradingSymbol' xlink:to='lab_dei_TradingSymbol'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey' xlink:label='dei_EntityCentralIndexKey'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityCentralIndexKey' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Registrant CIK</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityCentralIndexKey' xlink:to='lab_dei_EntityCentralIndexKey'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince' xlink:label='dei_EntityAddressStateOrProvince'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityAddressStateOrProvince' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Address, State or Province</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityAddressStateOrProvince' xlink:to='lab_dei_EntityAddressStateOrProvince'/>
	</link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>utmd-20221025_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2022 [PPXK5GW761L0VGS139PY]. www.edgarsuite.com -->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase"
		xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
		xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"
		xmlns:fil="http://utahmed.com/20221025"
		xmlns:link="http://www.xbrl.org/2003/linkbase"
		xmlns:xlink="http://www.w3.org/1999/xlink"
		xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
		xmlns:xbrli="http://www.xbrl.org/2003/instance">
	<link:roleRef roleURI="http://utahmed.com/20221025/role/idr_DocumentDocumentAndEntityInformation" xlink:type="simple" xlink:href="utmd-20221025.xsd#idr_DocumentDocumentAndEntityInformation"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://utahmed.com/20221025/role/idr_DocumentDocumentAndEntityInformation">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey' xlink:label='dei_EntityCentralIndexKey'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityCentralIndexKey' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate' xlink:label='dei_CurrentFiscalYearEndDate'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_CurrentFiscalYearEndDate' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName' xlink:label='dei_EntityRegistrantName'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityRegistrantName' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType' xlink:label='dei_DocumentType'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_DocumentType' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate' xlink:label='dei_DocumentPeriodEndDate'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_DocumentPeriodEndDate' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol' xlink:label='dei_TradingSymbol'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_TradingSymbol' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName' xlink:label='dei_SecurityExchangeName'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_SecurityExchangeName' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber' xlink:label='dei_EntityTaxIdentificationNumber'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityTaxIdentificationNumber' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding' xlink:label='dei_EntityCommonStockSharesOutstanding'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityCommonStockSharesOutstanding' use='optional' order='9.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat' xlink:label='dei_EntityPublicFloat'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityPublicFloat' use='optional' order='10.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory' xlink:label='dei_EntityFilerCategory'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityFilerCategory' use='optional' order='11.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus' xlink:label='dei_EntityCurrentReportingStatus'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityCurrentReportingStatus' use='optional' order='12.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent' xlink:label='dei_EntityInteractiveDataCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityInteractiveDataCurrent' use='optional' order='13.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers' xlink:label='dei_EntityVoluntaryFilers'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityVoluntaryFilers' use='optional' order='14.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer' xlink:label='dei_EntityWellKnownSeasonedIssuer'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityWellKnownSeasonedIssuer' use='optional' order='15.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany' xlink:label='dei_EntityShellCompany'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityShellCompany' use='optional' order='16.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness' xlink:label='dei_EntitySmallBusiness'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntitySmallBusiness' use='optional' order='17.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany' xlink:label='dei_EntityEmergingGrowthCompany'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityEmergingGrowthCompany' use='optional' order='18.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod' xlink:label='dei_EntityExTransitionPeriod'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityExTransitionPeriod' use='optional' order='19.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription' xlink:label='dei_AmendmentDescription'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_AmendmentDescription' use='optional' order='20.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode' xlink:label='dei_EntityIncorporationStateCountryCode'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityIncorporationStateCountryCode' use='optional' order='21.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber' xlink:label='dei_EntityFileNumber'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityFileNumber' use='optional' order='22.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1' xlink:label='dei_EntityAddressAddressLine1'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityAddressAddressLine1' use='optional' order='23.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown' xlink:label='dei_EntityAddressCityOrTown'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityAddressCityOrTown' use='optional' order='24.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince' xlink:label='dei_EntityAddressStateOrProvince'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityAddressStateOrProvince' use='optional' order='25.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode' xlink:label='dei_EntityAddressPostalZipCode'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityAddressPostalZipCode' use='optional' order='26.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode' xlink:label='dei_CityAreaCode'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_CityAreaCode' use='optional' order='27.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber' xlink:label='dei_LocalPhoneNumber'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_LocalPhoneNumber' use='optional' order='28.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications' xlink:label='dei_WrittenCommunications'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_WrittenCommunications' use='optional' order='29.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial' xlink:label='dei_SolicitingMaterial'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_SolicitingMaterial' use='optional' order='30.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer' xlink:label='dei_PreCommencementTenderOffer'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_PreCommencementTenderOffer' use='optional' order='31.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer' xlink:label='dei_PreCommencementIssuerTenderOffer'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_PreCommencementIssuerTenderOffer' use='optional' order='32.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag' xlink:label='dei_AmendmentFlag'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_AmendmentFlag' use='optional' order='33.0'/>
	</link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>utmd-20221025.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2022 [PPXK5GW761L0VGS139PY]. www.edgarsuite.com -->
<schema xmlns='http://www.w3.org/2001/XMLSchema' xmlns:us-gaap='http://fasb.org/us-gaap/2021-01-31' xmlns:fil='http://utahmed.com/20221025' xmlns:dei='http://xbrl.sec.gov/dei/2021q4' xmlns:xlink='http://www.w3.org/1999/xlink' xmlns:xbrldt='http://xbrl.org/2005/xbrldt' targetNamespace='http://utahmed.com/20221025' xmlns:link='http://www.xbrl.org/2003/linkbase' xmlns:xbrli='http://www.xbrl.org/2003/instance' elementFormDefault='qualified' attributeFormDefault='unqualified'>
	<annotation>
		<appinfo>
			<link:linkbaseRef xlink:type="simple" xlink:href="utmd-20221025_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
			<link:linkbaseRef xlink:type="simple" xlink:href="utmd-20221025_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
			<link:linkbaseRef xlink:type="simple" xlink:href="utmd-20221025_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
			<link:roleType roleURI="http://utahmed.com/20221025/role/idr_DocumentDocumentAndEntityInformation" id="idr_DocumentDocumentAndEntityInformation">
				<link:definition>000010 - Document - Document and Entity Information</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
		</appinfo>
	</annotation>
	<import schemaLocation='http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd' namespace='http://www.xbrl.org/2003/instance'/>
	<import schemaLocation='http://www.xbrl.org/2005/xbrldt-2005.xsd' namespace='http://xbrl.org/2005/xbrldt'/>
	<import namespace='http://xbrl.sec.gov/dei/2021q4' schemaLocation='https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd'/>
	<import namespace='http://fasb.org/us-gaap/2021-01-31' schemaLocation='https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd'/>
	<import namespace='http://www.xbrl.org/dtr/type/2020-01-21' schemaLocation='https://www.xbrl.org/dtr/type/2020-01-21/types.xsd'/>
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140708231079024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Oct. 25, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Registrant CIK</a></td>
<td class="text">0000706698<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Registrant Name</a></td>
<td class="text">UTAH MEDICAL PRODUCTS, INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">SEC Form</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Period End date</a></td>
<td class="text">Oct. 25,  2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Tax Identification Number (TIN)</a></td>
<td class="text">87-0342734<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">UT<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-12575<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">7043 South 300 West<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Midvale<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">UT<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">84047<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">801<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">566-1200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>utmd-20221025_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="utmd-20221025.xsd" xlink:type="simple"/>
    <context id="D221025">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
        </entity>
        <period>
            <startDate>2022-10-25</startDate>
            <endDate>2022-10-25</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="D221025" id="fact1">0000706698</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="D221025" id="fact2">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="D221025">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="D221025">2022-10-25</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="D221025">UTAH MEDICAL PRODUCTS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="D221025">UT</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="D221025">000-12575</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="D221025">87-0342734</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="D221025">7043 South 300 West</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="D221025">Midvale</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="D221025">UT</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="D221025">84047</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="D221025">801</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="D221025">566-1200</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="D221025">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="D221025">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="D221025">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="D221025">false</dei:PreCommencementIssuerTenderOffer>
    <dei:EntityEmergingGrowthCompany contextRef="D221025">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MTG1X#SY['R73>RHY_U=3_ 102P,$%     @ $G9959>*NQS     $P(   L
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M;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( !)V657;657IX@,  )<.   8
M          " @0X(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4
M    "  2=EE5GZ ;\+$"  #B#   #0              @ $F#   >&PO<W1Y
M;&5S+GAM;%!+ 0(4 Q0    ( !)V6567BKL<P    !,"   +
M  "  0(/  !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( !)V654<.&7J/P$  #P"
M   /              "  >L/  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4
M"  2=EE5)!Z;HJT   #X 0  &@              @ %7$0  >&PO7W)E;',O
M=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    "  2=EE599!YDAD!  #/ P
M$P              @ $\$@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08
.."0 ) #X"  "&$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>19</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="utmd-20221025.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000010 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://utahmed.com/20221025/role/idr_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="utmd-20221025.htm">utmd-20221025.htm</File>
    <File>utah_ex99z1.htm</File>
    <File>utmd-20221025.xsd</File>
    <File>utmd-20221025_def.xml</File>
    <File>utmd-20221025_lab.xml</File>
    <File>utmd-20221025_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="19">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "utmd-20221025.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "definitionLink": {
     "local": [
      "utmd-20221025_def.xml"
     ]
    },
    "inline": {
     "local": [
      "utmd-20221025.htm"
     ]
    },
    "labelLink": {
     "local": [
      "utmd-20221025_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "utmd-20221025_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "utmd-20221025.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 34,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021q4": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 19,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "fil",
   "nsuri": "http://utahmed.com/20221025",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "b",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20221025.htm",
      "contextRef": "D221025",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000010 - Document - Document and Entity Information",
     "role": "http://utahmed.com/20221025/role/idr_DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "b",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20221025.htm",
      "contextRef": "D221025",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://utahmed.com/20221025/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://utahmed.com/20221025/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://utahmed.com/20221025/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Fiscal Year End"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://utahmed.com/20221025/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Period End date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://utahmed.com/20221025/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "SEC Form"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://utahmed.com/20221025/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://utahmed.com/20221025/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://utahmed.com/20221025/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://utahmed.com/20221025/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://utahmed.com/20221025/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Registrant CIK"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://utahmed.com/20221025/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Number of common stock shares outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://utahmed.com/20221025/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Current with reporting"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://utahmed.com/20221025/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://utahmed.com/20221025/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://utahmed.com/20221025/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://utahmed.com/20221025/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://utahmed.com/20221025/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://utahmed.com/20221025/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://utahmed.com/20221025/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://utahmed.com/20221025/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://utahmed.com/20221025/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://utahmed.com/20221025/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://utahmed.com/20221025/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Tax Identification Number (TIN)"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://utahmed.com/20221025/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Voluntary filer"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://utahmed.com/20221025/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://utahmed.com/20221025/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://utahmed.com/20221025/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://utahmed.com/20221025/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://utahmed.com/20221025/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Trading Exchange"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://utahmed.com/20221025/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://utahmed.com/20221025/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://utahmed.com/20221025/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://utahmed.com/20221025/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_TextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Details"
       }
      }
     },
     "localname": "TextBlockAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r7": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r8": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001096906-22-002547-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001096906-22-002547-xbrl.zip
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M272*T!UB1B$.253N 0SQCX7'Y01 "',[ !(E]SV><B8.TBV,+>+.G'V""4(
MGYQXO3<AF[L87?,3J 0"&6!O[B,M+=.6V!4#C!YTBW9>I"-P'CN9!X[+#(K"
M6BK*\\$/V,BU PJ%XO@248+C0OHHS67 FQ@1!^+!.88Q*I!$)XC[S"P,.=N%
M;4663SU)Q&P0\KMZG4$;"OC#1_:MB*,,N8O!3ERG'=%BYP$/X1M;L98*?O+O
M(W<AB!:>6G@3^P[V "G[$2%DC_\#A$JSX!["$$O1''Q\'OAWP#TP%?TT!DAF
MW,8= YR)P#$!:KL84,:<!((+4>]'T_1*4.@Z'BPE\@.Y'"#V&1Y>1BY0*&R
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MQ$M9*;B8LP-3[X,L ;;W4Y5R(#ADWTC0D.>"BD]1UN..75#ICD ?99X>=.'
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MUY_+1MY+*ZD#UNZ6+:>M00>Q FFK^;BJF'78 >OD7FJ;!V8-ZD,:H6V]=(Y
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M@4_3P,44G+HNGD%%X.0V<>3)I'Z ^,.5UT\.Z.SBR:*KFF3YE'Z?#KD_J7P
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M[H*$%[4";.L\($JODLTWU!95?XAJ[3'\NA]' 9>#!P&N!?+6_J'E*P<PS>G
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MQX9!8)B%G>[13Z4YU*\1V-JC8!">G)P$6>N:6!\L5@_J]6,?!7EC54QVQ/)
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M\\?\6\OY_K]02P$"% ,4    "  2=EE5Q4QF.R@]  "O# ( #P
M    @ $     =71A:%]E>#DY>C$N:'1M4$L! A0#%     @ $G995;SBH'#[
M#0  O5L  !$              ( !53T  '5T;60M,C R,C$P,C4N:'1M4$L!
M A0#%     @ $G9958K'PN[@ @  6 D  !$              ( !?TL  '5T
M;60M,C R,C$P,C4N>'-D4$L! A0#%     @ $G9953BN.R\6 @  )@<  !4
M             ( !CDX  '5T;60M,C R,C$P,C5?9&5F+GAM;%!+ 0(4 Q0
M   ( !)V657 I>*;- @  %Q/   5              "  ==0  !U=&UD+3(P
M,C(Q,#(U7VQA8BYX;6Q02P$"% ,4    "  2=EE5LFX*1K %  #0-   %0
M            @ $^60  =71M9"TR,#(R,3 R-5]P<F4N>&UL4$L%!@     &
-  8 A $  "%?      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
